<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK274564" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK274564/" /><meta name="ncbi_pagename" content="Fibrous Dysplasia/McCune-Albright Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Fibrous Dysplasia/McCune-Albright Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Fibrous Dysplasia/McCune-Albright Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/06/27" /><meta name="citation_author" content="Alison M Boyce" /><meta name="citation_author" content="Pablo Florenzano" /><meta name="citation_author" content="Luis F de Castro" /><meta name="citation_author" content="Michael T Collins" /><meta name="citation_pmid" content="25719192" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK274564/" /><meta name="citation_keywords" content="FD/MAS" /><meta name="citation_keywords" content="FD/MAS" /><meta name="citation_keywords" content="Guanine nucleotide-binding protein G(s) subunit alpha isoforms short" /><meta name="citation_keywords" content="GNAS" /><meta name="citation_keywords" content="Fibrous Dysplasia/McCune-Albright Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Fibrous Dysplasia/McCune-Albright Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Alison M Boyce" /><meta name="DC.Contributor" content="Pablo Florenzano" /><meta name="DC.Contributor" content="Luis F de Castro" /><meta name="DC.Contributor" content="Michael T Collins" /><meta name="DC.Date" content="2019/06/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK274564/" /><meta name="description" content="Fibrous dysplasia/McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating pathogenic variant in GNAS (encoding the cAMP pathway-associated G-protein, Gsα), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because Gsα signaling is ubiquitous, additional tissues may be affected." /><meta name="og:title" content="Fibrous Dysplasia/McCune-Albright Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Fibrous dysplasia/McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating pathogenic variant in GNAS (encoding the cAMP pathway-associated G-protein, Gsα), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because Gsα signaling is ubiquitous, additional tissues may be affected." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK274564/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mccune-albright/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK274564/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89A9A4E04137810000000003C601A8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK274564_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK274564_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/feingold/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fhs/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK274564_"><span class="title" itemprop="name">Fibrous Dysplasia/McCune-Albright Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: FD/MAS</div><p class="contrib-group"><span itemprop="author">Alison M Boyce</span>, MD, <span itemprop="author">Pablo Florenzano</span>, MD, <span itemprop="author">Luis F de Castro</span>, PhD, and <span itemprop="author">Michael T Collins</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK274564_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK274564_ai__"><div class="contrib half_rhythm"><span itemprop="author">Alison M Boyce</span>, MD<div class="affiliation small">Skeletal Disorders and Mineral Homeostasis Section<br />Craniofacial and Skeletal Diseases Branch<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland</div><div class="affiliation small">Division of Endocrinology and Diabetes, Children&#x02019;s National Health System<br />Bone Health Program<br />Division of Orthopaedics and Sports Medicine<br />Children&#x02019;s National Health System<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@maecyob" class="oemail">vog.hin.liam@maecyob</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Pablo Florenzano</span>, MD<div class="affiliation small">Skeletal Disorders and Mineral Homeostasis Section<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland</div><div class="affiliation small">Endocrinology Department<br />Pontificia Universidad Catolica de Chile<br />Santiago, Chile<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@onaznerolf.olbap" class="oemail">vog.hin@onaznerolf.olbap</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Luis F de Castro</span>, PhD<div class="affiliation small">Skeletal Disorders and Mineral Homeostasis Section<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@zaidortsacedzednanref.siul" class="oemail">vog.hin@zaidortsacedzednanref.siul</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael T Collins</span>, MD<div class="affiliation small">Chief, Skeletal Disorders and Mineral Homeostasis Section<br />Craniofacial and Skeletal Diseases Branch<br />National Institute of Dental and Craniofacial Research<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.rcdin.rid@snillocm" class="oemail">vog.hin.rcdin.rid@snillocm</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 26, 2015</span>; Last Revision: <span itemprop="dateModified">June 27, 2019</span>.</p><p><em>Estimated reading time: 36 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mccune-albright.Summary" itemprop="description"><h2 id="_mccune-albright_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>GNAS</i> (encoding the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because G<sub>s</sub>&#x003b1; signaling is ubiquitous, additional tissues may be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>Caf&#x000e9; au lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. Fibrous dysplasia (FD), which can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton, can range from an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a>, asymptomatic monostotic lesion discovered incidentally to severe disabling polyostotic disease involving practically the entire skeleton and leading to progressive scoliosis, facial deformity, and loss of mobility, vision, and/or hearing. Endocrinopathies include:</p><ul><li class="half_rhythm"><div>Gonadotropin-independent precocious puberty resulting from recurrent ovarian cysts in girls and autonomous testosterone production in boys;</div></li><li class="half_rhythm"><div>Testicular lesions with or without associated gonadotropin-independent precocious puberty;</div></li><li class="half_rhythm"><div>Thyroid lesions with or without non-autoimmune hyperthyroidism;</div></li><li class="half_rhythm"><div>Growth hormone excess;</div></li><li class="half_rhythm"><div>FGF23-mediated phosphate wasting with or without hypophosphatemia in association with fibrous dysplasia; and</div></li><li class="half_rhythm"><div>Neonatal hypercortisolism.</div></li></ul><p>The prognosis for individuals with FD/MAS is based on disease location and severity.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>In most individuals, the diagnosis of FD/MAS is based on the finding of two or more typical clinical features. In individuals whose only clinical finding is monostotic fibrous dysplasia, identification of a somatic activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>GNAS</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is required to establish the diagnosis. Variant detection depends on the level of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in the tissue and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the technique.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management is most effectively accomplished by a multidisciplinary team of specialists.</p><ul><li class="half_rhythm"><div>FD. Management focuses on optimizing function and minimizing morbidity related to fractures and deformity (including scoliosis).</div></li><li class="half_rhythm"><div>Precocious puberty. Treatment prevents bone age advancement and compromise of adult height. For girls, the aromatase inhibitor letrozole is used; for boys, treatment options are less well established.</div></li><li class="half_rhythm"><div>Thyroid disease. Methimazole effectively manages hyperthyroidism; however, because hyperthyroidism is persistent, thyroidectomy is common.</div></li><li class="half_rhythm"><div>Growth hormone excess. Medical therapy is the preferred first-line treatment; options include (alone or in combination) octreotide and the growth hormone receptor antagonist pegvisomant.</div></li><li class="half_rhythm"><div>Hypercortisolism. Treatment varies by the presentation of neonatal Cushing syndrome.</div></li></ul><p><i>Surveillance:</i></p><p>FD/MAS. Monitor for the following:</p><ul><li class="half_rhythm"><div>Infants: clinical signs of hypercortisolism</div></li><li class="half_rhythm"><div>All children: growth acceleration and other clinical signs of precocious puberty and/or growth hormone excess</div></li><li class="half_rhythm"><div>Children:</div><ul><li class="half_rhythm"><div>Age &#x0003c;5 years: thyroid function abnormalities</div></li><li class="half_rhythm"><div>With thyroid abnormalities on ultrasound examination but normal thyroid function: periodic monitoring of thyroid function</div></li></ul></li><li class="half_rhythm"><div>Males: testicular lesions (physical examination and testicular ultrasound)</div></li><li class="half_rhythm"><div>Individuals on:</div><ul><li class="half_rhythm"><div>Pegvisomant: hepatotoxicity</div></li><li class="half_rhythm"><div>Somatostatin analogs: signs and symptoms of gallbladder disease</div></li></ul></li><li class="half_rhythm"><div>Females: breast cancer (earlier than is recommended for the general population)</div></li></ul><p>FD</p><ul><li class="half_rhythm"><div>Periodic radiographs to monitor existing FD and development of new lesions</div></li><li class="half_rhythm"><div>Periodic serum phosphorus (for development of hypophosphatemia) and 25-hydroxyvitamin D levels</div></li><li class="half_rhythm"><div>Craniofacial FD: yearly vision and hearing evaluations; periodic skull CT; routine serum IGF-1 levels through young adulthood</div></li><li class="half_rhythm"><div>Spine FD: close monitoring for progressive scoliosis</div></li></ul><p><i>Agents/circumstances to avoid:</i> Contact sports and other high-risk activities (when skeletal involvement is significant); prophylactic optic nerve decompression (in individuals with craniofacial FD); surgical removal of ovarian cysts; radiation therapy for treatment of FD; risk factors for malignancy (e.g., radiation exposure).</p></div><div><h4 class="inline">Genetic counseling.</h4><p>FD/MAS is not inherited. No parent of a child with FD/MAS has been demonstrated to have any significant, distinctive manifestations of the disorder. The risk to sibs is expected to be the same as in the general population. There are no verified instances of vertical transmission of FD/MAS.</p></div></div><div id="mccune-albright.Diagnosis"><h2 id="_mccune-albright_Diagnosis_">Diagnosis</h2><p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is usually diagnosed on clinical grounds, although formal diagnostic criteria have not been published.</p><div id="mccune-albright.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) <b>should be suspected</b> in individuals with any of the following skin, skeletal, or endocrine features.</p><p><b>Skin.</b> Individuals may have characteristic caf&#x000e9; au lait skin macules.</p><ul><li class="half_rhythm"><div>Borders are jagged and irregular, often referred to as resembling the "coast of Maine" (in contrast to the smooth-bordered "coast of California" lesions seen in <a href="/books/n/gene/nf1/">neurofibromatosis type 1</a>).</div></li><li class="half_rhythm"><div>Distribution shows an association with ("respecting") the midline of the body and following the developmental lines of Blaschko, which reflect patterns of embryonic cell migration (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F1/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF1" rid-ob="figobmccunealbrightF1">Figure 1</a>).</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmccunealbrightF1" co-legend-rid="figlgndmccunealbrightF1"><a href="/books/NBK274564/figure/mccune-albright.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figmccunealbrightF1" rid-ob="figobmccunealbrightF1"><img class="small-thumb" src="/books/NBK274564/bin/mccune-albright-Image014.gif" src-large="/books/NBK274564/bin/mccune-albright-Image014.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndmccunealbrightF1"><h4 id="mccune-albright.F1"><a href="/books/NBK274564/figure/mccune-albright.F1/?report=objectonly" target="object" rid-ob="figobmccunealbrightF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Caf&#x000e9; au lait skin pigmentation A. Skin lesions in a newborn demonstrating the characteristic association with the midline of the body, and distribution reflecting patterns of embryonic cell migration (developmental lines of Blaschko)</p></div></div><p><b>Skeletal.</b> Fibrous dysplasia (FD), a condition in which normal bone and bone marrow are replaced by fibroosseous tissue, results in an increased risk of fractures, deformity, functional impairment, and pain.</p><ul><li class="half_rhythm"><div>FD can be classified as monostotic (i.e., involvement of 1 bone) or polyostotic (i.e., involvement of &#x0003e;1 bone).</div></li><li class="half_rhythm"><div>FD can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2">Figure 2</a>).</div></li><li class="half_rhythm"><div>The initial radiologic evaluation for FD should include a 99Tc-MDP bone scan.</div><ul><li class="half_rhythm"><div>Areas of skeletal involvement identified on scintigraphy should be further evaluated with radiographs and head computerized tomography (CT), depending on the location and extent of the disease.</div></li><li class="half_rhythm"><div>See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3">Figure 3</a> for the suggested evaluations used to diagnose FD.</div></li></ul></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmccunealbrightF2" co-legend-rid="figlgndmccunealbrightF2"><a href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2"><img class="small-thumb" src="/books/NBK274564/bin/mccune-albright-Image015.gif" src-large="/books/NBK274564/bin/mccune-albright-Image015.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndmccunealbrightF2"><h4 id="mccune-albright.F2"><a href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-ob="figobmccunealbrightF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Fibrous dysplasia (FD) A. Proximal femur FD demonstrating the typical ground-glass appearance with a coxa vara ("shepherd's crook") deformity</p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmccunealbrightF3" co-legend-rid="figlgndmccunealbrightF3"><a href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3"><img class="small-thumb" src="/books/NBK274564/bin/mccune-albright-Image016.gif" src-large="/books/NBK274564/bin/mccune-albright-Image016.jpg" alt="Figure 3. " /></a><div class="icnblk_cntnt" id="figlgndmccunealbrightF3"><h4 id="mccune-albright.F3"><a href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-ob="figobmccunealbrightF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Suggested evaluations to determine if fibrous dysplasia (FD) is present and the extent of disease if FD is present </p></div></div><p><b>Endocrine.</b> Findings may include the following:</p><ul><li class="half_rhythm"><div>Gonadotropin-independent precocious puberty</div></li><li class="half_rhythm"><div>Testicular lesions including Leydig and/or Sertoli cell hyperplasia with characteristic ultrasonographic features, with or without associated gonadotropin-independent precocious puberty (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">Figure 4B</a>)</div></li><li class="half_rhythm"><div>Thyroid lesions with characteristic ultrasonographic features, with or without non-autoimmune hyperthyroidism (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">Figures 4C</a> and <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">4D</a>)</div></li><li class="half_rhythm"><div>Growth hormone excess</div></li><li class="half_rhythm"><div>Fibroblast growth factor 23 (FGF23)-mediated phosphate wasting with or without hypophosphatemia</div></li><li class="half_rhythm"><div>Neonatal hypercortisolism</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmccunealbrightF4" co-legend-rid="figlgndmccunealbrightF4"><a href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" title="Figure 4. " class="img_link icnblk_img figpopup" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4"><img class="small-thumb" src="/books/NBK274564/bin/mccune-albright-Image017.gif" src-large="/books/NBK274564/bin/mccune-albright-Image017.jpg" alt="Figure 4. " /></a><div class="icnblk_cntnt" id="figlgndmccunealbrightF4"><h4 id="mccune-albright.F4"><a href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-ob="figobmccunealbrightF4">Figure 4. </a></h4><p class="float-caption no_bottom_margin">Ultrasonography A. Pelvic ultrasound in a girl age seven years, showing a complex unilateral ovarian cyst (defined by cross-hatches). The uterus is prepubertal in size (arrow).</p></div></div></div><div id="mccune-albright.Establishing_the_Diagnos"><h3>Establishing the Diagnosis</h3><p>The diagnosis of FD/MAS <b>is established</b> in individuals who have two or more typical clinical features of FD/MAS. In individuals whose only clinical finding is monostotic fibrous dysplasia, identification of a somatic activating <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is required to confirm the diagnosis (see <a class="figpopup" href="/books/NBK274564/table/mccune-albright.T.molecular_genetic_test/?report=objectonly" target="object" rid-figpopup="figmccunealbrightTmoleculargenetictest" rid-ob="figobmccunealbrightTmoleculargenetictest">Table 1</a>).</p><p>Molecular genetic testing approaches include <b>targeted analysis</b> of codons p.Arg201 and p.Gln227. Testing a <b>sample of the lesional tissue</b>, if possible, has the highest clinical <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> in <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-sequencing-based diagnostic methods:</p><ul><li class="half_rhythm"><div>~80% in lesional tissue</div></li><li class="half_rhythm"><div>~20%-30% in peripheral blood lymphocytes</div></li></ul><p>Note: (1) Variant detection depends on the level of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in the tissue and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the technique. Detection frequency of a variant at p.Arg201 using standard <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> was highest in endocrine organs and lowest in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> skin specimens [<a class="bk_pop" href="#mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</a>]. The ability to detect mosaicism affects the detection rate of the assay (see <a class="figpopup" href="/books/NBK274564/table/mccune-albright.T.molecular_genetic_test/?report=objectonly" target="object" rid-figpopup="figmccunealbrightTmoleculargenetictest" rid-ob="figobmccunealbrightTmoleculargenetictest">Table 1</a> and <a class="figpopup" href="/books/NBK274564/table/mccune-albright.T.techniques_to_detect_g/?report=objectonly" target="object" rid-figpopup="figmccunealbrightTtechniquestodetectg" rid-ob="figobmccunealbrightTtechniquestodetectg">Table 4</a>). (2) Targeted analysis may be performed by sequencing of <i>GNAS</i> exons 8 and 9. <i>GNAS</i> variants other than those previously reported to be associated with FD/MAS would likely be interpreted as variants of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a>. (3) G<sub>s</sub>&#x003b1; is expressed in nearly all tissues from both maternal and paternal <i>GNAS</i> alleles. However, <i>GNAS</i> is a complex <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> where alternative transcripts and additional phenotypes may result from <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a> (see <a href="#mccune-albright.Genetically_Related_Alle">Genetically Related Disorders</a> and <a href="#mccune-albright.Molecular_Genetics">Molecular Genetics</a>).</p><div id="mccune-albright.T.molecular_genetic_test" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Fibrous Dysplasia/McCune-Albright Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.T.molecular_genetic_test/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.T.molecular_genetic_test_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected</th><th id="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNAS</i></td><td headers="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis of lesion biopsy of exons 8 and 9&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg201His, p.Arg201Cys&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%-90%&#x000a0;<sup>7</sup><br />75%-100%&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Gln227Leu&#x000a0;<sup>6</sup></td><td headers="hd_h_mccune-albright.T.molecular_genetic_test_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mccune-albright.TF.1.1"><p class="no_margin">See <a href="/books/NBK274564/#mccune-albright.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="mccune-albright.TF.1.2"><p class="no_margin">See <a href="#mccune-albright.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="mccune-albright.TF.1.3"><p class="no_margin">Targeted analysis may be performed by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a><i>.</i> Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="mccune-albright.TF.1.4"><p class="no_margin">Testing tissue from a lesion biopsy has a higher clinical yield than testing a blood sample. The detection rate for a blood sample is ~20%-30% [<a class="bk_pop" href="#mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</a>, <a class="bk_pop" href="#mccune-albright.REF.kalfa.2006.839">Kalfa et al 2006</a>].</p></div></dd><dt>5. </dt><dd><div id="mccune-albright.TF.1.5"><p class="no_margin">Somatic <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in individuals with FD/MAS are known to occur at only one of two amino acid residues: p.Arg201 (&#x0003e;95% of pathogenic variants) [<a class="bk_pop" href="#mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</a>] or p.Gln227 (&#x0003c;5%) [<a class="bk_pop" href="#mccune-albright.REF.idowu.2007.691">Idowu et al 2007</a>].</p></div></dd><dt>6. </dt><dd><div id="mccune-albright.TF.1.6"><p class="no_margin">Rarely, other amino acid substitutions at p.Arg201 and at p.Gln227 have been detected (see <a href="#mccune-albright.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd><dt>7. </dt><dd><div id="mccune-albright.TF.1.7"><p class="no_margin">Variant detection depends on the level of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in the tissue and the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the technique. Variant detected at p.Arg201 using standard <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> was highest in endocrine organs and lowest in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> skin specimens [<a class="bk_pop" href="#mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</a>].</p></div></dd><dt>8. </dt><dd><div id="mccune-albright.TF.1.8"><p class="no_margin">When modified primers (peptide nucleic acid) [<a class="bk_pop" href="#mccune-albright.REF.bianco.2000.120">Bianco et al 2000</a>] and <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a> [<a class="bk_pop" href="#mccune-albright.REF.narumi.2013.e60525">Narumi et al 2013</a>] technologies are combined [<a class="bk_pop" href="#mccune-albright.REF.narumi.2013.e60525">Narumi et al 2013</a>], a p.Arg201 variant can be detected in virtually all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues and in leukocytes of up to 75% of individuals.</p></div></dd></dl></div></div></div></div></div><div id="mccune-albright.Clinical_Characteristics"><h2 id="_mccune-albright_Clinical_Characteristics_">Clinical Characteristics</h2><div id="mccune-albright.Clinical_Description"><h3>Clinical Description</h3><p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) results from mosaic somatic activating pathogenic variants in <i>GNAS</i>, which encodes the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;. Affected tissues can include those derived from ectoderm, mesoderm, and endoderm, and commonly include skin, skeleton, and certain endocrine organs. However, because G<sub>s</sub>&#x003b1; signaling is present in virtually every tissue, additional sites may be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p>The phenotypic spectrum of FD/MAS ranges from asymptomatic incidental findings to neonatal lethality. There is a high degree of variability between individuals, both in the number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues and the degree to which they are affected. Disease manifestations depend on the time during embryogenesis that the <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> occurred, the tissue involved, and the role of G<sub>s</sub>&#x003b1; in the affected tissue. Pathogenic variants occurring early in development lead to widespread disease, while those occurring later in development lead to limited disease.</p><p><b>Pigmented macules<i>.</i></b> Caf&#x000e9; au lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. There is no correlation between the size of the skin lesions and the extent of disease, nor between the distribution of skin lesions and the location of fibrous dysplasia.</p><p><b>Fibrous dysplasia of bone.</b> As with skin, fibrous dysplasia demonstrates a mosaic pattern: it can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton. The bones most commonly involved are the skull base and proximal femurs [<a class="bk_pop" href="#mccune-albright.REF.kelly.2008.57">Kelly et al 2008</a>]. While there is generally a central-to-peripheral gradient, any combination of involved bones is possible.</p><p>Fibrous dysplasia can manifest along a wide spectrum: from an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a>, asymptomatic monostotic lesion discovered incidentally to severe, disabling polyostotic disease involving practically the entire skeleton and leading to loss of vision, hearing, and/or mobility.</p><p>Individual bone lesions typically manifest during the first few years of life and expand during childhood. The vast majority of clinically significant bone lesions are detectable by age ten years, with few new and almost no clinically significant bone lesions appearing after age 15 years [<a class="bk_pop" href="#mccune-albright.REF.hart.2007.1468">Hart et al 2007</a>]. In adulthood, fibrous dysplasia lesions typically become less active, likely related to apoptosis of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>-bearing cells [<a class="bk_pop" href="#mccune-albright.REF.kuznetsov.2008.1731">Kuznetsov et al 2008</a>].</p><p>The clinical presentation and course of fibrous dysplasia (FD) depends on the location and extent of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> skeleton:</p><ul><li class="half_rhythm"><div><b>Appendicular skeleton</b></div><ul><li class="half_rhythm"><div>Children with fibrous dysplasia in the appendicular skeleton typically present with a limp, pain, and/or pathologic fractures.</div></li><li class="half_rhythm"><div>Recurrent fractures and progressive deformity may lead to difficulties with ambulation and loss of mobility.</div></li></ul></li><li class="half_rhythm"><div><b>Craniofacial region</b></div><ul><li class="half_rhythm"><div>FD may present as a painless "lump" or facial asymmetry.</div></li><li class="half_rhythm"><div>Expansion of craniofacial lesions may lead to progressive facial deformity (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2">Figure 2B</a>), and in rare cases (usually in association with growth hormone excess) loss of vision and/or hearing due to compromise of the optic nerves and/or external auditory canals [<a class="bk_pop" href="#mccune-albright.REF.cutler.2006.1011">Cutler et al 2006</a>, <a class="bk_pop" href="#mccune-albright.REF.boyce.2018.102">Boyce et al 2018</a>].</div></li></ul></li><li class="half_rhythm"><div><b>Vertebrae</b></div><ul><li class="half_rhythm"><div>FD involving the vertebrae is common, and may lead to scoliosis, which in rare instances may be severe, progressive, and even lethal [<a class="bk_pop" href="#mccune-albright.REF.leet.2004b.531">Leet et al 2004b</a>].</div></li><li class="half_rhythm"><div>Untreated, progressive scoliosis is one of the few features of FD that can lead to early morbidity.</div></li></ul></li></ul><p><b>Bone pain</b> is a common complication of fibrous dysplasia. Although bone pain may present at any age, it is common for bone pain to be absent in childhood, occur in adolescence, and progress into adulthood [<a class="bk_pop" href="#mccune-albright.REF.kelly.2008.57">Kelly et al 2008</a>].</p><p><b>Aneurysmal bone cysts</b> are rapidly expanding fluid-filled lesions that form within preexisting areas of FD. Such lesions are best detected by MRI. Affected individuals experience acute onset of severe pain, rapidly expanding localized deformity, and rarely &#x02013; when cysts compress the optic nerve &#x02013; rapid loss of vision. Aneurysmal bone cysts thus carry a high risk of morbidity (see <a href="#mccune-albright.Management">Management</a>).</p><p><b>Malignant transformation</b> of FD lesions is a rare complication. Many instances of malignant transformation were reported in association with previous radiation treatment [<a class="bk_pop" href="#mccune-albright.REF.ruggieri.1994.1411">Ruggieri et al 1994</a>]. Growth hormone excess may be a predisposing factor [<a class="bk_pop" href="#mccune-albright.REF.salenave.2014.1955">Salenave et al 2014</a>].</p><p><b>Radiographic appearance</b> of fibrous dysplasia varies according to location:</p><ul><li class="half_rhythm"><div>Radiographs of the appendicular skeleton show expansive lesions with endosteal scalloping, thinning of the cortex, and a "ground glass" appearance (<a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2">Figure 2A</a>).</div></li><li class="half_rhythm"><div>Fibrous dysplasia in the craniofacial skeleton is typically expansile and appears sclerotic on x-ray, but demonstrates a typical "ground glass" appearance on computed tomography (CT) (<a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2">Figure 2C</a>).</div></li><li class="half_rhythm"><div>With aging, fibrous dysplasia lesions in the appendicular skeleton tend to become sclerotic on radiographs and craniofacial fibrous dysplasia lesions develop a "cystic" appearance (<a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2">Figure 2D</a>).</div></li></ul><p><b>Endocrinopathies</b> can include any of the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Precocious puberty.</b> Precocious puberty is common in girls with FD/MAS (~85%), and is often the presenting feature. Recurrent ovarian cysts (<a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">Figure 4A</a>) lead to intermittent estrogen production resulting in breast development, growth acceleration, and vaginal bleeding; during the intervals between cyst formation, breast tissue typically regresses and estrogen levels fall to prepubertal levels. Ovarian cysts typically continue into adulthood, leading to irregular menses. This has the potential to interrupt ovulatory cycles, which may increase the time to conception in adult women. Ovarian torsion has been seen rarely in girls and women with large and persistent cysts [<a class="bk_pop" href="#mccune-albright.REF.clark.2000.204">Clark et al 2000</a>].</div><div class="half_rhythm">Precocious puberty is less common in boys with FD/MAS (~10%-15%), and is due to autonomous testosterone production [<a class="bk_pop" href="#mccune-albright.REF.boyce.2012a.e1782">Boyce et al 2012a</a>], which leads to progressive pubertal development including growth acceleration, pubic and axillary hair, acne, and aggressive and/or inappropriately sexual behavior.</div><div class="half_rhythm">In both girls and boys, prolonged autonomous sex steroid production typically leads to activation of the hypothalamic-pituitary axis and the development of central precocious puberty.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Fertility.</b> The effects of autonomous sex steroid production on pituitary-gonadal function and fertility in adults are not well characterized. Women with FD/MAS may have recurrent cysts leading to irregular menses in adulthood [<a class="bk_pop" href="#mccune-albright.REF.lala.2007.423">Lala et al 2007</a>]. While many women in the NIH cohort have achieved successful pregnancies, it is possible that interruption of ovulatory cycles could decrease fertility and increase the time to conception [Authors, personal observation].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Testicular abnormalities.</b> Testicular abnormalities are seen in the majority of boys and men with MAS (~85%), and typically manifest as unilateral or bilateral macroorchidism [<a class="bk_pop" href="#mccune-albright.REF.boyce.2012a.e1782">Boyce et al 2012a</a>]. Ultrasound examination demonstrates discrete hyper- and hypoechoic lesions and microlithiasis, corresponding to areas of Leydig and/or Sertoli cell hyperplasia (<a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">Figure 4B</a>).</div><div class="half_rhythm">The potential for malignant transformation of testicular lesions is unknown, but appears to be low [<a class="bk_pop" href="#mccune-albright.REF.boyce.2012a.e1782">Boyce et al 2012a</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Thyroid disease.</b> Thyroid involvement in FD/MAS is common. Approximately half of individuals with FD/MAS have ultrasound findings consistent with thyroid involvement, including mixed cystic and solid lesions interspersed with areas of normal-appearing tissue (<a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">Figure 4C</a> and <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F4/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF4" rid-ob="figobmccunealbrightF4">4D</a>) [<a class="bk_pop" href="#mccune-albright.REF.celi.2008.2383">Celi et al 2008</a>, <a class="bk_pop" href="#mccune-albright.REF.tessaris.2012.151">Tessaris et al 2012</a>].</div><div class="half_rhythm">Hyperthyroidism is present in 10% to 30% of individuals with FD/MAS, and results from both increased hormone production and increased conversion of thyroxine (T4) to triiodothyronine (T3) [<a class="bk_pop" href="#mccune-albright.REF.celi.2008.2383">Celi et al 2008</a>].</div><div class="half_rhythm">Hyperthyroidism is typically mild to moderate, but may be severe, and if undetected can lead to thyroid storm during anesthetic induction for surgery [<a class="bk_pop" href="#mccune-albright.REF.lawless.1992.1099">Lawless et al 1992</a>].</div><div class="half_rhythm">Uncontrolled hyperthyroidism may lead to bone age advancement, elevated bone turnover, and fractures.</div><div class="half_rhythm">Malignant transformation of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> thyroid tissue has rarely been reported [<a class="bk_pop" href="#mccune-albright.REF.collins.2003.4413">Collins et al 2003</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Growth hormone excess.</b> Approximately 15%-20% of individuals with FD/MAS harbor <i>GNAS</i> pathogenic variants in the anterior pituitary that can lead to autonomous growth hormone production; approximately 80% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with autonomous growth hormone production also have hyperprolactinemia [<a class="bk_pop" href="#mccune-albright.REF.salenave.2014.1955">Salenave et al 2014</a>].</div><div class="half_rhythm">Affected individuals typically present with linear growth acceleration, and may develop features of acromegaly. Clinically, growth hormone excess must be distinguished from precocious puberty and hyperthyroidism, which also present with growth acceleration.</div><div class="half_rhythm">Untreated growth hormone excess is associated with expansion of craniofacial fibrous dysplasia, leading to macrocephaly and increased risk of vision loss [<a class="bk_pop" href="#mccune-albright.REF.boyce.2013.e126">Boyce et al 2013</a>] (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F2/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF2" rid-ob="figobmccunealbrightF2">Figure 2B</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>FGF23-mediated phosphate wasting.</b> In the majority of individuals with FD, increased production of the phosphaturic hormone FGF23 in FD tissue results in a renal tubulopathy with some degree of phosphate wasting [<a class="bk_pop" href="#mccune-albright.REF.collins.2001.806">Collins et al 2001</a>]. However, frank hypophosphatemia in persons with FD is infrequent, in part due to alterations in FGF23 processing that takes place in FD tissue and results in increased cleavage of FGF23 to its inactive fragments [<a class="bk_pop" href="#mccune-albright.REF.bhattacharyya.2012.1132">Bhattacharyya et al 2012</a>]. The degree of FGF23 overproduction in FD correlates with disease severity and skeletal burden; thus, frank hypophosphatemia is only seen in individuals with a substantial FD burden [<a class="bk_pop" href="#mccune-albright.REF.riminucci.2003.683">Riminucci et al 2003</a>].</div><div class="half_rhythm">In contrast to most other features of FD/MAS, hypophosphatemia may wax and wane over the course of a person's lifetime and become more severe during periods of rapid skeletal growth. Hypophosphatemia may resolve as persons with FD become older, likely reflecting the intrinsic changes in FD that occur with age [<a class="bk_pop" href="#mccune-albright.REF.kuznetsov.2008.1731">Kuznetsov et al 2008</a>].</div><div class="half_rhythm">Affected individuals with frank hypophosphatemia may develop rickets/osteomalacia, increased fractures, and bone pain [<a class="bk_pop" href="#mccune-albright.REF.leet.2004a.571">Leet et al 2004a</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hypercortisolism.</b> Infants with FD/MAS may rarely present with Cushing syndrome due to excess cortisol production from the fetal adrenal gland [<a class="bk_pop" href="#mccune-albright.REF.brown.2010.1508">Brown et al 2010</a>, <a class="bk_pop" href="#mccune-albright.REF.carney.2011.1311">Carney et al 2011</a>]. Clinical symptoms typically develop in the neonatal period, and may be severe, leading to critical illness and death. Spontaneous regression has been reported in approximately half of survivors, presumably related to fetal adrenal involution.</div></li></ul><p><b>Liver</b></p><ul><li class="half_rhythm"><div>Hepatitis and neonatal cholestasis may be pronounced in infants, and generally wane with age to a mild persistent form [<a class="bk_pop" href="#mccune-albright.REF.silva.2000.154">Silva et al 2000</a>, <a class="bk_pop" href="#mccune-albright.REF.ikawa.2016.298">Ikawa et al 2016</a>].</div></li><li class="half_rhythm"><div>Hepatic adenomas with an identifiable <i>GNAS</i> activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have also been reported [<a class="bk_pop" href="#mccune-albright.REF.gaujoux.2014.e97">Gaujoux et al 2014</a>].</div></li><li class="half_rhythm"><div>Liver failure in adults with FD/MAS has not been described.</div></li></ul><p><b>Gastrointestinal</b></p><ul><li class="half_rhythm"><div>Gastroesophageal reflux manifests in childhood and may be severe.</div></li><li class="half_rhythm"><div>Upper gastrointestinal polyps have been recently described as a common finding in individuals with FD/MAS [<a class="bk_pop" href="#mccune-albright.REF.wood.2017.391">Wood et al 2017</a>].</div></li></ul><p><b>Pancreas.</b> Approximately 15% of individuals with FD/MAS have pancreatic complications:</p><ul><li class="half_rhythm"><div class="half_rhythm">Pancreatitis</div></li><li class="half_rhythm"><div class="half_rhythm">Intraductal papillary mucinous neoplasms (IPMN), which may present with variable grades of dysplasia [<a class="bk_pop" href="#mccune-albright.REF.gaujoux.2014.e97">Gaujoux et al 2014</a>, <a class="bk_pop" href="#mccune-albright.REF.wood.2017.391">Wood et al 2017</a>]</div><div class="half_rhythm">An individual with pancreatic carcinoma derived from an intestinal subtype of IPMN has been described [<a class="bk_pop" href="#mccune-albright.REF.parvanescu.2014.858">Parvanescu et al 2014</a>].</div></li></ul><p><b>Myxomas.</b> Intramuscular myxomas are benign, usually asymptomatic, and often found incidentally.</p><p><b>Hematology</b></p><ul><li class="half_rhythm"><div>Bone and bone marrow are, to varying degrees, replaced by fibroosseous tissue typically devoid of hematopoietic marrow.</div></li><li class="half_rhythm"><div>There have been reports of bone marrow failure with pancytopenia and extramedullary hematopoiesis requiring splenectomy in individuals with FD/MAS [<a class="bk_pop" href="#mccune-albright.REF.mahdi.2017.179">Mahdi et al 2017</a>, <a class="bk_pop" href="#mccune-albright.REF.robinson.2018.237">Robinson et al 2018</a>].</div></li></ul><p><b>Breast cancer.</b> The risk for breast cancer in women with FD/MAS may be increased and it can occur at a <b>younger</b> age compared to the general population. However, pathogenic activating <i>GNAS</i> variants were identified in only half of the breast tumors from women with FD/MAS studied [<a class="bk_pop" href="#mccune-albright.REF.majoor.2018a.84">Majoor et al 2018a</a>].</p><p><b>Health-related quality of life.</b> Several series have shown impaired physical functioning in individuals with FD/MAS, strongly correlated with disease severity. Nevertheless, individuals with this condition show preserved social and emotional functioning. This finding is important for prognosis and parental reassurance [<a class="bk_pop" href="#mccune-albright.REF.kelly.2005.388">Kelly et al 2005</a>, <a class="bk_pop" href="#mccune-albright.REF.majoor.2018b.23">Majoor et al 2018b</a>].</p></div><div id="mccune-albright.GenotypePhenotype_Correl"><h3>Genotype-Phenotype Correlations</h3><p>There are no known <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>.</p><p>To date, only activating <i>GNAS</i> somatic pathogenic variants at residues p.Arg201 and p.Gln227 have been identified in individuals with FD/MAS.</p><p>Disease severity is likely correlated with the degree of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> and the tissues that are affected.</p></div><div id="mccune-albright.Nomenclature"><h3>Nomenclature</h3><p>The association of intramuscular myxomas with FD/MAS has been termed "Mazabraud syndrome" [<a class="bk_pop" href="#mccune-albright.REF.cox.2017.589">Cox et al 2017</a>].</p></div><div id="mccune-albright.Prevalence"><h3>Prevalence</h3><p>FD/MAS is rare. While reliable data of prevalence are not available, estimates range between 1:100,000 and 1:1,000,000.</p><p>In contrast, fibrous dysplasia (particularly the monostotic form) is not rare, and has been estimated to account for as much as 7% of all benign bone tumors.</p><p>FD/MAS affects both sexes and shows no predilection for any particular populations.</p></div></div><div id="mccune-albright.Genetically_Related_Alle"><h2 id="_mccune-albright_Genetically_Related_Alle_">Genetically Related (Allelic) Disorders</h2><p>In contrast to somatic activating (<a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a>) variants at specific <i>GNAS</i> residues resulting in FD/MAS, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> (<a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a>) <i>GNAS</i> variants are associated with multiple phenotypes. Furthermore, since <i>GNAS</i> is an <a class="def" href="/books/n/gene/glossary/def-item/imprinted/">imprinted</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with germline inactivating pathogenic variants depends on the parent of origin (maternal vs paternal) for the mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and the degree of <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a> that occurs in a given tissue. <a class="figpopup" href="/books/NBK274564/table/mccune-albright.T.allelic_disorders_caus/?report=objectonly" target="object" rid-figpopup="figmccunealbrightTallelicdisorderscaus" rid-ob="figobmccunealbrightTallelicdisorderscaus">Table 2</a> lists phenotypes with germline inactivating <i>GNAS</i> pathogenic variants (see <a href="/books/n/gene/gnas-dis/">Disorders of <i>GNAS</i> Inactivation</a>).</p><div id="mccune-albright.T.allelic_disorders_caus" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Allelic Disorders Caused by Germline Inactivating (Loss-of-Function) <i>GNAS</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.T.allelic_disorders_caus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.T.allelic_disorders_caus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNAS</i> Variant</th><th id="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM / Reference</th></tr></thead><tbody><tr><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pseudopseudohypoparathyroidism</td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inactivating <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of the paternal <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/612463" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612463</a></td></tr><tr><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pseudohypoparathyroidism Ia</td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inactivating <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of the maternal <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in exons 1-12</td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/103580" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">103580</a></td></tr><tr><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pseudohypoparathyroidism Ib</td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Imprinting defect: <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of regulatory elements in the maternal <i>GNAS</i> complex <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>&#x000a0;<sup>1</sup></td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/603233" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603233</a></td></tr><tr><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pseudohypoparathyroidism Ic</td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inactivating <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 13 of the maternal <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/612462" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612462</a></td></tr><tr><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive osseous heteroplasia</td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inactivating <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of the paternal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></td><td headers="hd_h_mccune-albright.T.allelic_disorders_caus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/166350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">166350</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mccune-albright.TF.2.1"><p class="no_margin">Pseudohypoparathyroidism Ib can also be caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>STX16</i>.</p></div></dd></dl></div></div></div><p>Sporadic tumors (including pituitary, pancreatic, breast, and colorectal tumors) occurring as single tumors in the absence of any other findings of FD/MAS frequently harbor somatic activating variants in <i>GNAS</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable. For more information see Molecular Genetics, <a href="#mccune-albright.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>.</p></div><div id="mccune-albright.Differential_Diagnosis"><h2 id="_mccune-albright_Differential_Diagnosis_">Differential Diagnosis</h2><p><a href="/books/n/gene/nf1/"><b>Neurofibromatosis type 1</b></a>
<b>(NF1)</b> and FD/MAS have several overlapping features, including caf&#x000e9; au lait macules and skeletal abnormalities. Skin findings in NF1 include six or more caf&#x000e9; au lait macules, which are generally smooth bordered ("coast of California," as opposed to the irregularly bordered "coast of Maine" lesions seen in FD/MAS). Skeletal features of NF1 include kyphoscoliosis, sphenoid dysplasia, cortical thinning of long bones, and bowing and dysplasia, particularly of the tibia, which may result in pseudarthroses. Distinct features of NF1 include tumors of the nervous system such as neurofibromas and optic gliomas, pigmented iris hamartomas, and axillary freckling. NF1 is caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>NF1</i> and is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p><b>Cutaneous-skeletal hypophosphatemia syndrome</b> is a mosaic disorder resulting from somatic activating pathogenic variants in <i>HRAS</i> and <i>NRAS</i> [<a class="bk_pop" href="#mccune-albright.REF.lim.2014.397">Lim et al 2014</a>]<i>.</i> Affected individuals develop cutaneous lesions (epidermal and large <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> melanocytic nevi) following a mosaic distribution, a mosaic skeletal dysplasia, overproduction of FGF23 resulting in rickets/osteomalacia, and variable other associated anomalies of the eye, brain, and vasculature [<a class="bk_pop" href="#mccune-albright.REF.ovejero.2016.3615">Ovejero et al 2016</a>].</p><p><b>Fibroosseous skeletal lesions</b> may have radiologic and/or histologic features similar to fibrous dysplasia. These lesions are typically solitary, are not associated with extraskeletal features, and do not harbor pathogenic variants in <i>GNAS</i>.</p><ul><li class="half_rhythm"><div><b>Giant cell tumors of bone</b> are acquired lesions with histopathologic features similar to fibrous dysplasia, including proliferation of bone marrow stromal cells and the presence of multiple multinucleated giant cells. Giant cell tumors are typically benign, but may result in localized bone destruction and (rarely) metastases.</div></li><li class="half_rhythm"><div><b>Ossifying fibromas</b> are benign lesions typically affecting the mandible and maxillae and presenting with local expansion of a firm, painless mass. Ossifying fibromas are generally more aggressive than craniofacial fibrous dysplasia lesions, and are treated with surgical excision.</div></li><li class="half_rhythm"><div><b>Osteofibrous dysplasia</b> lesions typically occur in children younger than age ten years, and most commonly affect the anterior tibia. Affected children present with painless localized swelling and, in rare cases, with fracture or progressive deformity. Radiographs show a well-circumscribed radiolucent lesion with a characteristic sclerotic rim along the intra-cortical surface.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/cherubism/"><b>Cherubism</b></a> is characterized by progressive fibroosseous lesions of the mandible and maxilla primarily. It typically presents in early childhood with bilateral symmetric enlargement of the lower face leading to a characteristic "cherubic" appearance in which the eyes appear to gaze upward because of maxillary involvement. Facial deformity progresses during childhood and early puberty, after which it sometimes spontaneously regresses. In most cases, cherubism arises from <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>SH3BP2</i>. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li></ul></div><div id="mccune-albright.Management"><h2 id="_mccune-albright_Management_">Management</h2><div id="mccune-albright.Evaluations_Following_In"><h3>Evaluations Following Initial Diagnosis</h3><p>After the initial diagnosis, all individuals with fibrous dysplasia/McCune-Albright syndrome (FD/MAS) should be evaluated to determine the extent of disease. The presence of any features of FD/MAS should prompt more detailed clinical evaluation for additional manifestations. The authors recommend the following studies, if they have not already been completed.</p><p><b>Skeleton</b></p><ul><li class="half_rhythm"><div>Total body bone scintigraphy to identify and determine the extent of FD [<a class="bk_pop" href="#mccune-albright.REF.collins.2005.219">Collins et al 2005</a>]. The majority of clinically significant skeletal lesions are apparent on bone scan by age five years.</div></li><li class="half_rhythm"><div>Imaging of areas of identified areas of FD with radiographs (axial and appendicular FD) and/or computed tomography (craniofacial FD) to more clearly evaluate the extent and anatomy of the lesions</div></li><li class="half_rhythm"><div>Baseline ophthalmologic, otolaryngologic, and audiologic evaluations in persons with craniofacial FD</div></li><li class="half_rhythm"><div>Skeletal evaluation (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3">Figure 3</a>)</div></li></ul><p><b>Endocrine.</b> A thorough history and physical examination and review of a growth chart (if available) are recommended to evaluate for clinical signs of endocrinopathies.</p><ul><li class="half_rhythm"><div>Biochemical screening for hyperthyroidism, growth hormone excess (IGF-1 level), and FGF23-mediated hypophosphatemia (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3">Figure 3</a>, <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F6/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF6" rid-ob="figobmccunealbrightF6">Figure 6</a>, and <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F7/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF7" rid-ob="figobmccunealbrightF7">Figure 7</a>)</div></li><li class="half_rhythm"><div>In individuals with clinical signs or a previous history of precocious puberty: biochemical screening, pelvic ultrasound examination (females), and bone age examination (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F5/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF5" rid-ob="figobmccunealbrightF5">Figure 5</a> and <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F6/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF6" rid-ob="figobmccunealbrightF6">Figure 6</a>)</div></li><li class="half_rhythm"><div>Ultrasound examination of the thyroid gland and testes (in all males) to evaluate for subclinical disease (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F7/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF7" rid-ob="figobmccunealbrightF7">Figure 7</a> and <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F8/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF8" rid-ob="figobmccunealbrightF8">Figure 8</a>)</div></li><li class="half_rhythm"><div>Test for hypercortisolism in infants with clinical evidence of Cushing syndrome (hypertension, facial plethora, abdominal obesity, developmental delay, failure to thrive, small for gestational age) (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F9/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF9" rid-ob="figobmccunealbrightF9">Figure 9</a>).</div></li></ul><p><b>Less common manifestations.</b> Consideration should be given to the less common manifestations cited in <a href="#mccune-albright.Clinical_Description">Clinical Description</a> with appropriate clinical evaluations and imaging/biochemical studies performed as indicated (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F10/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF10" rid-ob="figobmccunealbrightF10">Figure 10</a> for gastrointestinal evaluation).</p><div id="mccune-albright.F5" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image001.jpg" alt="Figure 5. " /></div><h3><span class="label">Figure 5. </span></h3><div class="caption"><p>Recommended evaluations for growth hormone excess in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div><div id="mccune-albright.F6" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image002.jpg" alt="Figure 6. " /></div><h3><span class="label">Figure 6. </span></h3><div class="caption"><p>Recommended evaluations for gonadal abnormalities in females with fibrous dysplasia/McCune-Albright syndrome</p></div></div><div id="mccune-albright.F7" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image003.jpg" alt="Figure 7. " /></div><h3><span class="label">Figure 7. </span></h3><div class="caption"><p>Recommended evaluations for gonadal abnormalities in males with fibrous dysplasia/McCune-Albright syndrome</p></div></div><div id="mccune-albright.F8" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image004.jpg" alt="Figure 8. " /></div><h3><span class="label">Figure 8. </span></h3><div class="caption"><p>Recommended evaluations for thyroid abnormalities in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div><div id="mccune-albright.F9" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image005.jpg" alt="Figure 9. " /></div><h3><span class="label">Figure 9. </span></h3><div class="caption"><p>Recommended evaluations for adrenal gland dysfunction in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div><div id="mccune-albright.F10" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image006.jpg" alt="Figure 10. " /></div><h3><span class="label">Figure 10. </span></h3><div class="caption"><p>Recommended evaluations for gastrointestinal issues in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div></div><div id="mccune-albright.Treatment_of_Manifestati"><h3>Treatment of Manifestations</h3><p>Management is most effectively accomplished through the input of a multidisciplinary team of specialists including an endocrinologist, orthopedic surgeon, physiatrist, ophthalmologist, audiologist, endocrine surgeon, craniofacial surgeon, and clinical geneticist. No consensus management guidelines have been published.</p><div id="mccune-albright.Fibrous_Dysplasia"><h4>Fibrous Dysplasia</h4><p>There are no available medical therapies capable of altering the disease course in fibrous dysplasia. Current management is focused on optimizing function and minimizing morbidity related to fractures and deformity. The primary elements of management include the following (see also <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F11/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF11" rid-ob="figobmccunealbrightF11">Figure 11</a>):</p><ul><li class="half_rhythm"><div>Orthopedic surgery to repair fractures and to prevent and correct deformities. A surgeon experienced in FD should be consulted, as approaches previously considered standard (e.g., curettage, grafting, external fixation) are frequently ineffective [<a class="bk_pop" href="#mccune-albright.REF.stanton.2012.s1">Stanton et al 2012</a>, <a class="bk_pop" href="#mccune-albright.REF.leet.2016.211">Leet et al 2016</a>].</div></li><li class="half_rhythm"><div>Diagnosis and treatment of scoliosis is of particular importance, as it may be rapidly progressive and in rare cases may lead to fatal respiratory compromise. For this reason, all individuals with spinal FD should be monitored closely by an orthopedic surgeon or physiatrist for possible progression. Surgical fusion has been shown to be effective at stabilizing the spine [<a class="bk_pop" href="#mccune-albright.REF.leet.2004b.531">Leet et al 2004b</a>, <a class="bk_pop" href="#mccune-albright.REF.mancini.2009.196">Mancini et al 2009</a>].</div></li><li class="half_rhythm"><div>Aneurysmal bone cysts, best detected by MRI, are rapidly expanding fluid-filled lesions that form within preexisting areas of FD. Affected individuals experience acute onset of severe pain, rapidly expanding localized deformity, and rarely &#x02013; when cysts compress the optic nerve &#x02013; rapid loss of vision. Aneurysmal bone cysts thus carry a high risk of morbidity and should be evaluated urgently by a surgeon [<a class="bk_pop" href="#mccune-albright.REF.lee.2012.s2">Lee et al 2012</a>, <a class="bk_pop" href="#mccune-albright.REF.manjila.2013.1183">Manjila et al 2013</a>].</div></li><li class="half_rhythm"><div>Prophylactic optic nerve decompression to reduce the risk of vision loss can in fact increase the risk of vision loss and is thus contraindicated [<a class="bk_pop" href="#mccune-albright.REF.lee.2002.1670">Lee et al 2002</a>, <a class="bk_pop" href="#mccune-albright.REF.cutler.2006.1011">Cutler et al 2006</a>, <a class="bk_pop" href="#mccune-albright.REF.amit.2011.e25179">Amit et al 2011</a>].</div></li><li class="half_rhythm"><div>Physical therapy to optimize function and attenuate loss of mobility is appropriate. Affected individuals with lower-extremity FD in particular may benefit from therapies to address hip girdle weakness, range of motion, and leg length discrepancies [<a class="bk_pop" href="#mccune-albright.REF.paul.2014.41">Paul et al 2014</a>].</div></li><li class="half_rhythm"><div>Intravenous bisphosphonates such as zoledronic acid and pamidronate are usually effective at relieving bone pain. Dosing should be based on symptoms, not on a fixed interval or bone turnover markers. The oral bisphosphonate alendronate has been shown to be ineffective for treatment of bone pain [<a class="bk_pop" href="#mccune-albright.REF.boyce.2014.4133">Boyce et al 2014</a>].</div></li><li class="half_rhythm"><div>Denosumab, a human monoclonal antibody to RANKL, has been used in several cases of FD, with an apparent significant reduction in pain, bone turnover markers, and tumor growth rate. However, it has also been associated with clinically significant disturbances of mineral metabolism both while on treatment and after discontinuation [<a class="bk_pop" href="#mccune-albright.REF.boyce.2012b.1462">Boyce et al 2012b</a>, <a class="bk_pop" href="#mccune-albright.REF.benhamou.2014.549">Benhamou et al 2014</a>, <a class="bk_pop" href="#mccune-albright.REF.ganda.2014.777">Ganda &#x00026; Seibel 2014</a>]. For this reason, we only recommend the use of denosumab in centers with large experience in the treatment of individuals with FD, ideally in the context of a clinical study.</div></li><li class="half_rhythm"><div>Malignancy should remain a consideration for individuals with acute or rapidly expanding FD lesions, or with atypical radiographic features such as compromise of the bony cortex with an associated soft tissue mass.</div></li></ul><div id="mccune-albright.F11" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image007.jpg" alt="Figure 11. " /></div><h3><span class="label">Figure 11. </span></h3><div class="caption"><p>Recommended management for fibrous dysplasia in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div></div><div id="mccune-albright.Endocrinopathies"><h4>Endocrinopathies</h4><p><b>Precocious puberty.</b> Treatment of precocious puberty is important to prevent bone age advancement and compromise of adult height.</p><ul><li class="half_rhythm"><div><b>Females</b> (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F12/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF12" rid-ob="figobmccunealbrightF12">Figure 12</a>). The aromatase inhibitor letrozole is an effective treatment for females [<a class="bk_pop" href="#mccune-albright.REF.feuillan.2007.2100">Feuillan et al 2007</a>]. In a recently published study with the longest follow up to date, letrozole treatment resulted in sustained beneficial effects on skeletal maturation, growth velocity, and predicted adult height [<a class="bk_pop" href="#mccune-albright.REF.estrada.2016.477">Estrada et al 2016</a>]. Most females also have a decrease in the number of menstrual bleeding episodes while on treatment. Prophylactic surgical intervention for large and persistent ovarian cysts should be undertaken with extreme caution due to the known risk for cyst recurrence and the potential for decreased ovarian reserve in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> women.</div></li><li class="half_rhythm"><div><b>Males</b> (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F13/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF13" rid-ob="figobmccunealbrightF13">Figure 13</a>). Given the rarity of precocious puberty in males, treatment options are less well established. One strategy includes the combination of an androgen receptor blocker (e.g., spironolactone or bicalutamide) and an inhibitor of sex steroid synthesis (e.g., letrozole) [<a class="bk_pop" href="#mccune-albright.REF.boyce.2012a.e1782">Boyce et al 2012a</a>].</div></li></ul><p>Children of both sexes frequently enter central precocious puberty due to premature sex steroid exposure (see <a href="#mccune-albright.Clinical_Description">Clinical Description</a>). This typically presents with reappearance of the signs of puberty in a child with previously well-controlled peripheral precocious puberty. Leuprolide therapy in combination with the above medications is an effective therapeutic strategy in most.</p><div id="mccune-albright.F12" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image008.jpg" alt="Figure 12. " /></div><h3><span class="label">Figure 12. </span></h3><div class="caption"><p>Recommended management for precocious puberty in girls with fibrous dysplasia/McCune-Albright syndrome</p></div></div><div id="mccune-albright.F13" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image009.jpg" alt="Figure 13. " /></div><h3><span class="label">Figure 13. </span></h3><div class="caption"><p>Recommended management for gonadal involvement in boys with fibrous dysplasia/McCune-Albright syndrome</p></div></div><p><b>Thyroid disease.</b> Methimazole is effective for medical management of hyperthyroidism [<a class="bk_pop" href="#mccune-albright.REF.tessaris.2012.151">Tessaris et al 2012</a>] and is the first line of treatment. Propilthiouracil has been associated with an unacceptable risk of hepatotoxicity in children and therefore is no longer recommended [<a class="bk_pop" href="#mccune-albright.REF.ross.2016.1343">Ross et al 2016</a>]. Because FD/MAS-associated hyperthyroidism is persistent, most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals ultimately elect for definitive treatment. Thyroidectomy is the preferred definitive treatment in most affected individuals. Total gland resection is generally recommended due to the potential for thyroid tissue regrowth. Selection of an experienced high-volume endocrine surgeon is critical to minimize complications and optimize outcomes. Affected individuals should be monitored post-surgically with yearly ultrasound examination to evaluate for tissue regrowth. See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F14/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF14" rid-ob="figobmccunealbrightF14">Figure 14</a>.</p><p>Radioablation is typically avoided due to potential preferential uptake by tissues bearing a somatic activating <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, which may lead to increased risk of malignancy in the remaining unaffected gland. Additionally, <i>GNAS</i> pathogenic variants are associated with a slight increased risk of malignant transformation in both thyroid and non-thyroidal tissues; the risk is potentially enhanced by radiation exposure.</p><div id="mccune-albright.F14" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image010.jpg" alt="Figure 14. " /></div><h3><span class="label">Figure 14. </span></h3><div class="caption"><p>Recommended management for hyperthyroidism in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div><p><b>Growth hormone (GH) excess.</b> Medical therapy is the preferred first-line treatment. Options include (alone or in combination) somatostatin analogs and the growth hormone receptor antagonist pegvisomant [<a class="bk_pop" href="#mccune-albright.REF.boyce.2013.e126">Boyce et al 2013</a>, <a class="bk_pop" href="#mccune-albright.REF.salenave.2014.1955">Salenave et al 2014</a>] (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F15/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF15" rid-ob="figobmccunealbrightF15">Figure 15</a>).</p><ul><li class="half_rhythm"><div>In growing children, the therapeutic goal is to maintain the IGF-1 level in the middle of the normal range with an IGF-1 Z-score below 0.</div></li><li class="half_rhythm"><div>In skeletally mature individuals, the goal is to decrease the IGF-1 level to as low as possible.</div></li></ul><p>Medical therapy is typically continued indefinitely, as options for definitive treatment are associated with significant morbidity. Surgery may be technically difficult or precluded due to craniofacial FD. Additionally, given the diffuse pituitary infiltration of GH-producing cells, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals treated surgically require total hypophysectomy with resulting total hypopituitarism [<a class="bk_pop" href="#mccune-albright.REF.vortmeyer.2012.2404">Vortmeyer et al 2012</a>]. Radiation treatment may be effective in refractory cases, but has been associated with fatal malignant transformation of craniofacial FD [<a class="bk_pop" href="#mccune-albright.REF.hansen.2003.79">Hansen &#x00026; Moffat 2003</a>, <a class="bk_pop" href="#mccune-albright.REF.liu.2011.283">Liu et al 2011</a>].</p><p>The hyperprolactinemia that frequently accompanies growth hormone excess is generally responsive to treatment with dopamine agonists, including cabergoline and bromocriptine. This class of drugs could also have an effect on growth hormone excess treatment in those with modest elevations of GH and IGF-1 levels, with or without concomitant hyperprolactinemia [<a class="bk_pop" href="#mccune-albright.REF.katznelson.2014.3933">Katznelson et al 2014</a>].</p><div id="mccune-albright.F15" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image011.jpg" alt="Figure 15. " /></div><h3><span class="label">Figure 15. </span></h3><div class="caption"><p>Recommended management for growth hormone excess in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div><p><b>FGF23-mediated phosphate wasting.</b> Treatment of frank hypophosphatemia is the same as in other disorders of FGF23 excess, and includes oral phosphorus and calcitriol. Important therapeutic endpoints include growth velocity and radiographic evidence of epiphyseal healing. Unlike other disorders of FGF23 excess, bone turnover markers in FD/MAS (e.g., alkaline phosphatase) may be constitutively elevated and are not a useful indicator of skeletal response to treatment.</p><p><b>Hypercortisolism.</b> Treatment guidelines for hypercortisolism are difficult to establish given the rarity of neonatal Cushing syndrome. Additionally, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may be critically ill at presentation, which significantly affects treatment options.</p><ul><li class="half_rhythm"><div>Definitive treatment includes surgical removal of the diseased adrenal glands.</div></li><li class="half_rhythm"><div>For medical treatment metyrapone is frequently effective, and is preferred over ketoconazole in children with liver abnormalities.</div></li></ul><p>Spontaneous remission has been clearly documented in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#mccune-albright.REF.brown.2010.1508">Brown et al 2010</a>]; however, it is not possible to identify prospectively which individuals will undergo remission. The decision to pursue or delay adrenalectomy must be made on an individual basis, taking into account the severity of illness, the ability of medications to control cortisol levels, and the potential effect of continued hypercortisolism on neurodevelopment. See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F16/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF16" rid-ob="figobmccunealbrightF16">Figure 16</a>.</p><div id="mccune-albright.F16" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image012.jpg" alt="Figure 16. " /></div><h3><span class="label">Figure 16. </span></h3><div class="caption"><p>Recommended management for hypercortisolism in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div><p><b>Pancreatic involvement.</b> Natural history and specific risk of malignancy in FD/MAS-associated intraductal papillary mucinous neoplasms (IPMNs) have not been defined. Until that information becomes available, the authors recommend following guidelines for the evaluation of IPMNs in the general population [<a class="bk_pop" href="#mccune-albright.REF.tanaka.2012.183">Tanaka et al 2012</a>] (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F17/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF17" rid-ob="figobmccunealbrightF17">Figure 17</a>).</p><div id="mccune-albright.F17" class="figure bk_fig"><div class="graphic"><img src="/books/NBK274564/bin/mccune-albright-Image013.jpg" alt="Figure 17. " /></div><h3><span class="label">Figure 17. </span></h3><div class="caption"><p>Recommended management for pancreatic involvement in individuals with fibrous dysplasia/McCune-Albright syndrome</p></div></div></div></div><div id="mccune-albright.Surveillance"><h3>Surveillance</h3><p>Due to the mosaic nature of this condition, the clinical findings in any given <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual can vary significantly, with some individuals having involvement of only one organ system and others having more widespread involvement. Additionally, some features are age dependent and are either not likely to develop after a certain age or are more likely to affect an older individual as opposed to a child. The following information on surveillance applies to individuals who have already been evaluated for signs and symptoms of the condition and in whom the extent of disease has been assessed; surveillance will need to be tailored to the individual's age and known affected organ systems (see <a class="figpopup" href="/books/NBK274564/table/mccune-albright.T.surveillance_to_consid/?report=objectonly" target="object" rid-figpopup="figmccunealbrightTsurveillancetoconsid" rid-ob="figobmccunealbrightTsurveillancetoconsid">Table 3</a>).</p><div id="mccune-albright.Fibrous_Dysplasia_1"><h4>Fibrous Dysplasia</h4><p>See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3">Figure 3</a>.</p><ul><li class="half_rhythm"><div>Individuals with craniofacial FD should have yearly vision and hearing evaluations, and periodic computed tomography of the skull.</div></li><li class="half_rhythm"><div>Individuals with spine FD should be monitored closely for progressive scoliosis.</div></li><li class="half_rhythm"><div>Radiographs should be performed periodically to evaluate new or worsening symptoms and to provide additional information about FD anatomy and bone quality.</div></li><li class="half_rhythm"><div>Phosphorus levels should be checked periodically to monitor for the development of FGF23-mediated hypophosphatemia.</div></li><li class="half_rhythm"><div>25-hydroxyvitamin D levels should be monitored periodically as part of routine bone health surveillance.</div></li></ul></div><div id="mccune-albright.Endocrinopathies_1"><h4>Endocrinopathies</h4><p><b>Precocious puberty.</b> All children should be monitored for growth acceleration and other clinical signs of precocious puberty (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F5/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF5" rid-ob="figobmccunealbrightF5">Figure 5</a>).</p><p><b>Testicular lesions.</b> It is prudent to monitor all males with regular physical examinations and testicular ultrasound examinations (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F7/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF7" rid-ob="figobmccunealbrightF7">Figure 7</a>).</p><p><b>Thyroid.</b> Thyroid function tests (TSH, free T4, and T3) should be performed routinely in all children younger than age five years.</p><ul><li class="half_rhythm"><div>Individuals with abnormalities on thyroid ultrasound examination but normal thyroid function tests should continue to have laboratory testing periodically throughout childhood, as the development of frank hyperthyroidism may occur later (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F8/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF8" rid-ob="figobmccunealbrightF8">Figure 8</a>).</div></li><li class="half_rhythm"><div>Affected individuals who retain abnormal thyroid tissue following thyroid surgery should be monitored with regular physical examination and periodic thyroid ultrasound examination because of the potential for thyroid tissue regrowth (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F14/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF14" rid-ob="figobmccunealbrightF14">Figure 14</a>).</div></li></ul><p><b>Growth hormone excess.</b> All children should be monitored for growth acceleration.</p><ul><li class="half_rhythm"><div>Affected individuals with significant craniofacial FD should have IGF-1 levels monitored routinely through early adulthood.</div></li><li class="half_rhythm"><div>Affected individuals treated medically with somatostatin analogs should be monitored for gallbladder disease, and those treated with pegvisomant should be monitored for hepatotoxicity (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F15/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF15" rid-ob="figobmccunealbrightF15">Figure 15</a>).</div></li></ul><p><b>FGF23-mediated phosphate wasting.</b> Serum phosphorus levels should be monitored routinely in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3">Figure 3</a>).</p><p><b>Hypercortisolism.</b> Routine biochemical surveillance is not indicated; however, all infants should be monitored for clinical signs of hypercortisolism.</p><p>Affected individuals with a history of Cushing syndrome that has spontaneously resolved should be monitored for late-appearing adrenal insufficiency (see <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F9/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF9" rid-ob="figobmccunealbrightF9">Figure 9</a>).</p></div><div id="mccune-albright.Malignancies"><h4>Malignancies</h4><p>While a strong association between certain pathogenic variants (i.e., activating <i>GNAS</i> variants at residues p.Arg201 and p.Gln227) and malignancies in FD/MAS is lacking, it is prudent to minimize additional risk factors (e.g., radiation exposure) and encourage vigilance and monitoring.</p><p>Given the higher risk of breast cancer in women with FD/MAS, screening should be considered at a younger age than what is recommended for the general population [<a class="bk_pop" href="#mccune-albright.REF.majoor.2018a.84">Majoor et al 2018a</a>].</p><div id="mccune-albright.T.surveillance_to_consid" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Surveillance to Consider for Individuals with Fibrous Dysplasia/McCune Albright Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.T.surveillance_to_consid/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.T.surveillance_to_consid_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" rowspan="3" colspan="2" scope="row" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal&#x000a0;<sup>1</sup></b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitoring for progression of scoliosis &#x00026; other skeletal findings by orthopedic surgeon or physiatrist</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Routinely</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Computed tomography of the skull</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 5 yrs or potentially sooner in younger individuals, those w/severe disease, or if vision or hearing deficits develop</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Radiographs to evaluate new or worsening symptoms &#x00026; to provide additional information about FD anatomy &#x00026; bone quality</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" rowspan="13" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Endocrine</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><b>Puberty (females)</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation for growth acceleration &#x00026; other clinical signs of precocious puberty&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Bone age assessment</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 6 mos in those w/bone age advancement of &#x02265;2 yrs</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" rowspan="4" colspan="1" scope="row" style="text-align:left;vertical-align:middle;"><b>Puberty (males)</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation for growth acceleration &#x00026; other clinical signs of precocious puberty&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Bone age assessment</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 6 mos in those w/bone age advancement of &#x02265;2 yrs</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Testicular physical examination</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Testicular ultrasound</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" rowspan="3" colspan="1" scope="row" style="text-align:left;vertical-align:middle;"><b>Thyroid</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thyroid function tests (TSH, free T4, T3)</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Routinely in all children age &#x0003c;5 yrs; every 4-6 mos in children &#x0003c;3 yrs &#x00026; annually in children &#x0003e;3 yrs throughout childhood if ultrasound abnormalities are present&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Physical examination of the thyroid</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically in those w/retained abnormal thyroid tissue following thyroidectomy&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Thyroid ultrasound</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically in those w/abnormalities on thyroid ultrasound or who have undergone thyroidectomy&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" rowspan="4" colspan="1" scope="row" style="text-align:left;vertical-align:middle;"><b>Adrenal&#x000a0;<sup>7</sup></b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical signs of hypercortisolism&#x000a0;<sup>8</sup></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In infants at each visit</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Signs &#x00026; symptoms of late-appearing adrenal insufficiency in those w/history of Cushing syndrome that has spontaneously resolved&#x000a0;<sup>7</sup></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Serum IGF-1 levels</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Routinely through young adulthood in those w/craniofacial FD</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">For signs &#x00026; symptoms of gallbladder disease in those treated w/somatostatin analogs</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Renal</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum phosphorus &#x00026; 25-hydroxyvitamin D levels&#x000a0;<sup>1,&#x000a0;9</sup></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation by ophthalmologist (or neuroophthamologist)</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually in those w/craniofacial FD</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>ENT</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation by audiologist</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually in those w/craniofacial FD</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evidence of hepatotoxicity for those on pegvisomant</td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr><tr><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Oncology</b></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider initiating breast cancer screening earlier than recommended for general population.&#x000a0;<sup>10</sup></td><td headers="hd_h_mccune-albright.T.surveillance_to_consid_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Periodically</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mccune-albright.TF.3.1"><p class="no_margin">See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F3/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF3" rid-ob="figobmccunealbrightF3">Figure 3</a>.</p></div></dd><dt>2. </dt><dd><div id="mccune-albright.TF.3.2"><p class="no_margin">See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F6/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF6" rid-ob="figobmccunealbrightF6">Figure 6</a>.</p></div></dd><dt>3. </dt><dd><div id="mccune-albright.TF.3.3"><p class="no_margin">Growth acceleration can also be a sign of growth hormone excess.</p></div></dd><dt>4. </dt><dd><div id="mccune-albright.TF.3.4"><p class="no_margin">Individuals with abnormalities on thyroid ultrasound examination but normal thyroid function tests are at risk for the development of frank hyperthyroidism.</p></div></dd><dt>5. </dt><dd><div id="mccune-albright.TF.3.5"><p class="no_margin">See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F14/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF14" rid-ob="figobmccunealbrightF14">Figure 14</a>.</p></div></dd><dt>6. </dt><dd><div id="mccune-albright.TF.3.6"><p class="no_margin">Thyroid tissue can regrow after thyroidectomy.</p></div></dd><dt>7. </dt><dd><div id="mccune-albright.TF.3.7"><p class="no_margin">See <a class="figpopup" href="/books/NBK274564/figure/mccune-albright.F9/?report=objectonly" target="object" rid-figpopup="figmccunealbrightF9" rid-ob="figobmccunealbrightF9">Figure 9</a>.</p></div></dd><dt>8. </dt><dd><div id="mccune-albright.TF.3.8"><p class="no_margin">Routine biochemical surveillance for hypercortisolism is not indicated.</p></div></dd><dt>9. </dt><dd><div id="mccune-albright.TF.3.9"><p class="no_margin">To monitor for the development of FGF23-mediated hypophosphatemia and as part of routine bone health</p></div></dd><dt>10. </dt><dd><div id="mccune-albright.TF.3.10"><p class="no_margin"><a class="bk_pop" href="#mccune-albright.REF.majoor.2018a.84">Majoor et al [2018a]</a></p></div></dd></dl></div></div></div></div></div><div id="mccune-albright.AgentsCircumstances_to_A"><h3>Agents/Circumstances to Avoid</h3><p>Contact sports and other high-risk activities should be avoided in those with significant skeletal involvement.</p><p>Avoid prophylactic optic nerve decompression (see <a href="#mccune-albright.Treatment_of_Manifestati">Treatment of Manifestations</a>).</p><p>Surgical removal of ovarian cysts should be performed with caution and only in limited circumstances.</p><p>Radiation therapy is not indicated for treatment of FD, and radiation exposure to FD lesions should be limited due to potential risk for malignant transformation [<a class="bk_pop" href="#mccune-albright.REF.ruggieri.1994.1411">Ruggieri et al 1994</a>].</p><p>Radioablation for hyperthyroidism is also typically avoided due to potential preferential uptake by tissues bearing a somatic activating <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, which may lead to increased risk of malignancy in the remaining unaffected gland.</p></div><div id="mccune-albright.Evaluation_of_Relatives"><h3>Evaluation of Relatives at Risk</h3><p>Because FD/MAS is not inherited, relatives are not at increased risk and do not require evaluation.</p><p>See <a href="#mccune-albright.Related_Genetic_Counseli">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mccune-albright.Pregnancy_Management"><h3>Pregnancy Management</h3><p>While the effects of pregnancy on bone and endocrine disease in women with FD/MAS are not well studied, in the authors' experience most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> women do not experience a worsening of disease during pregnancy.</p></div><div id="mccune-albright.Therapies_Under_Investig"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="mccune-albright.Genetic_Counseling"><h2 id="_mccune-albright_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mccune-albright.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is not inherited.</p><ul><li class="half_rhythm"><div>Verified vertical transmission has never been observed.</div></li><li class="half_rhythm"><div>Molecular data indicates that all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are mosaic for an activating <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that arises sporadically early in embryonic development.</div></li></ul></div><div id="mccune-albright.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> No parent of a child with FD/MAS has been demonstrated to have any significant, distinctive manifestations of the disorder, nor would such a finding be expected given the somatic nature of the disease.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Given the somatic mutational mechanism of FD/MAS, the risk for an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib would be expected to be the same as in the general population.</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> There are no verified instances of vertical transmission of FD/MAS, potentially the result of embryonic lethality.</p><p><b>Other family members.</b> The risk to other family members is the same as that in the general population.</p></div><div id="mccune-albright.Related_Genetic_Counseli"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> mosaic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> Counseling for recurrence risks in FD/MAS should emphasize that, while no pregnancy is at zero risk, evidence suggests that the risk of recurrence for this disorder is not increased over that of the general population.</p><p><b>Family planning.</b> It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mccune-albright.Prenatal_Testing"><h3>Prenatal Testing</h3><p>As FD/MAS is the result of postzygotic somatic mutation of <i>GNAS</i> and is not inherited, prenatal testing for FD/MAS is not indicated.</p></div></div><div id="mccune-albright.Resources"><h2 id="_mccune-albright_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association des Malades Porteurs du Syndrome de McCune-Albright, de Dysplasie Fibreuse des Os</b></div><div>France</div><div><b>Phone:</b> 09 77 39 12 60; 06 76 34 15 69</div><div><b>Email:</b> assymcal@orange.fr</div><div><a href="http://www.assymcal.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.assymcal.org</a></div></li><li class="half_rhythm"><div><b>European Association for McCune-Albright Syndrome and Other Rare Diseases</b></div><div>Italy</div><div><b>Email:</b> info@eamas.net</div><div><a href="http://www.eamas.net/main.php?language=en" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.eamas.net</a></div></li><li class="half_rhythm"><div><b>Fibrous Dysplasia Foundation</b></div><div><b>Email:</b> info@fibrousdysplasia.org</div><div><a href="http://fibrousdysplasia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fibrousdysplasia.org</a></div></li><li class="half_rhythm"><div><b>Fibrous Dysplasia Support Society</b></div><div>United Kingdom</div><div><b>Email:</b> enquiries@FDSSUK.org.uk</div><div><a href="http://www.fdssuk.org.uk/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fdssuk.org.uk</a></div></li><li class="half_rhythm"><div><b>MAGIC Foundation</b></div><div>6645 West North Avenue</div><div>Oak Park IL 60302</div><div><b>Email:</b> ContactUs@magicfoundation.org</div><div><a href="https://www.magicfoundation.org/Growth-Disorders/McCune-Albright-Syndrome-or-Fibrous-Dysplasia/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">McCune-Albright Syndrome / Fibrous Dysplasia</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001217.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">McCune-Albright syndrome</a></div></li><li class="half_rhythm"><div><b>Pati&#x000eb;ntenvereniging Fibreuze Dysplasie</b></div><div>Netherlands</div><div><b>Email:</b> info@fibreuzedysplasie.eu</div><div><a href="http://www.fibreuzedysplasie.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fibreuzedysplasie.eu</a></div></li></ul></div><div id="mccune-albright.Molecular_Genetics"><h2 id="_mccune-albright_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mccune-albright.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Fibrous Dysplasia/McCune-Albright Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mccune-albright.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mccune-albright.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mccune-albright.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mccune-albright.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mccune-albright.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mccune-albright.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mccune-albright.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2778" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GNAS</i></a></td><td headers="hd_b_mccune-albright.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2778" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">20q13<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_mccune-albright.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P63092" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Guanine nucleotide-binding protein G(s) subunit alpha isoforms short</a></td><td headers="hd_b_mccune-albright.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/GNAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GNAS complex locus (GNAS) @ LOVD</a></td><td headers="hd_b_mccune-albright.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GNAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GNAS</a></td><td headers="hd_b_mccune-albright.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GNAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GNAS</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mccune-albright.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mccune-albright.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Fibrous Dysplasia/McCune-Albright Syndrome (<a href="/omim/139320,174800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/139320" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">139320</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GNAS COMPLEX LOCUS; GNAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/174800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">174800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MCCUNE-ALBRIGHT SYNDROME; MAS</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>GNAS</i> is a complex <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> with an <a class="def" href="/books/n/gene/glossary/def-item/imprinted/">imprinted</a> expression pattern. Multiple <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> products, including maternally, paternally, and biallelically expressed transcripts, are derived from the use of four promoters and 5' exons that splice onto a common set of downstream exons [<a class="bk_pop" href="#mccune-albright.REF.weinstein.2004.5459">Weinstein et al 2004</a>] (summarized in OMIM <a href="http://omim.org/entry/139320" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">139320</a>). The major <i>GNAS</i> product is the ubiquitously expressed G<sub>s</sub>&#x003b1;, which is generated by the most downstream promoter (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1). For a detailed summary of gene and protein information, see <a href="/books/NBK274564/#mccune-albright.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants at p.Arg201 has been identified in more than 95% of all published reports of FD/MAS. The most frequent missense pathogenic variants are p.Arg201His and p.Arg201Cys [<a class="bk_pop" href="#mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</a>]. Very infrequently, arginine is replaced by serine, glycine, or leucine. Rarely, missense variants at p.Gln227 have been reported [<a class="bk_pop" href="#mccune-albright.REF.idowu.2007.691">Idowu et al 2007</a>].</p><p>There are ongoing experimental approaches to develop methods with increased <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> [<a class="bk_pop" href="#mccune-albright.REF.bianco.2000.120">Bianco et al 2000</a>, <a class="bk_pop" href="#mccune-albright.REF.narumi.2013.e60525">Narumi et al 2013</a>, <a class="bk_pop" href="#mccune-albright.REF.de_sanctis.2017.342">de Sanctis et al 2017</a>] that in the future may enable the use of peripheral blood lymphocytes (PBL) for <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detection and also allow the quantification of the mutated to wild type cell ratio within the sample (as opposed to presence-absence in <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-RFLP techniques):</p><div id="mccune-albright.T.techniques_to_detect_g" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Techniques to Detect <i>GNAS</i> Somatic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.T.techniques_to_detect_g/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.T.techniques_to_detect_g_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Detection Rate</th></tr><tr><th headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2" id="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Blood</th><th headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2" id="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lesional tissue</th></tr></thead><tbody><tr><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant-specific amplification by <a class="def" href="/books/n/gene/glossary/def-item/polymerase-chain-reaction/">polymerase chain reaction</a> (<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>) &#x00026;/or restriction enzyme digestion (RFLP) followed by directed sequencing of the variant loci&#x000a0;<sup>1</sup></td><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2 hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~20%-30%</td><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2 hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~80%</td></tr><tr><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> with peptide-nucleic acid probes&#x000a0;<sup>2</sup> combined w/<a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a> (PNA-<a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">NGS</a>)&#x000a0;<sup>3</sup></td><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2 hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~75%</td><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2 hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td></tr><tr><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Co-amplification at lower denaturation temperature and <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-based TaqMan <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a> (real-time COLD-MAMA-<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>)&#x000a0;<sup>4</sup></td><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2 hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~75%</td><td headers="hd_h_mccune-albright.T.techniques_to_detect_g_1_1_1_2 hd_h_mccune-albright.T.techniques_to_detect_g_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mccune-albright.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al [2004]</a>, <a class="bk_pop" href="#mccune-albright.REF.kalfa.2006.839">Kalfa et al [2006]</a></p></div></dd><dt>2. </dt><dd><div id="mccune-albright.TF.4.2"><p class="no_margin"><a class="bk_pop" href="#mccune-albright.REF.bianco.2000.120">Bianco et al [2000]</a></p></div></dd><dt>3. </dt><dd><div id="mccune-albright.TF.4.3"><p class="no_margin"><a class="bk_pop" href="#mccune-albright.REF.narumi.2013.e60525">Narumi et al [2013]</a></p></div></dd><dt>4. </dt><dd><div id="mccune-albright.TF.4.4"><p class="no_margin"><a class="bk_pop" href="#mccune-albright.REF.de_sanctis.2017.342">de Sanctis et al [2017]</a></p></div></dd></dl></div></div></div><p>Recent studies implicate alternate transcripts of <i>GNAS</i> in the pathogenesis of FD/MAS. A p.Arg543His variant, corresponding to position p.Arg201His in G&#x003b1;s, on the large XL&#x003b1;s transcript of G&#x003b1;s, was detected in individuals with a paternal <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, whereas mutated neuroendocrine secretory protein 55 (NESP55) variant transcript was detected in those with a maternal pathogenic variant in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues. Functional in vitro assays of wild type XL&#x003b1;s showed strong induction of adenyl cyclase activity in transfected cells, suggesting that this <i>GNAS</i> variant could be playing a role in the pathogenesis of FD [<a class="bk_pop" href="#mccune-albright.REF.mariot.2011">Mariot et al 2011</a>].</p><div id="mccune-albright.T.gnas_somatic_variants" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>GNAS</i> Somatic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK274564/table/mccune-albright.T.gnas_somatic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mccune-albright.T.gnas_somatic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.601C&#x0003e;T</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg201Cys</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_3" rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000516.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000516<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000507.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000507<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.601C&#x0003e;G</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg201Gly</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.601C&#x0003e;A</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg201Ser</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.602G&#x0003e;A</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg201His</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.602G&#x0003e;T</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg201Leu</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.679C&#x0003e;A</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln227Lys</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.680A&#x0003e;T</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln227Leu</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.680A&#x0003e;G</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln227Arg</td></tr><tr><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.681G&#x0003e;T</td><td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln227His</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>GNAS</i> encodes the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;. G<sub>s</sub>&#x003b1; is a key component of many hormonal and other signal transduction pathways. Its primary role is to couple G-coupled protein receptors to adenylyl cyclase, promoting receptor-stimulated production of intracellular cAMP. G<sub>s</sub>&#x003b1; in its inactive state forms a heterotrimer with the G<sub>s</sub>&#x003b2; and G<sub>s</sub>&#x003b3; subunits, with GDP bound to its binding site. Ligand binding to the G-coupled protein receptor promotes release of GDP from the &#x003b1;-subunit and binding of GTP. The GTP-bound G<sub>s</sub>&#x003b1; dissociates from the &#x003b2;-&#x003b3; heterotrimer and translocates to interact with adenylyl cyclase to promote cAMP production. Intrinsic GTPase hydrolyzes the bound GTP to GDP, leading to cessation of cAMP generation and reassembly of the &#x003b1;-&#x003b2;-&#x003b3; heterotrimer. Downstream, cAMP is metabolized to AMP by one of many tissue-dependent phosphodiesterases.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The FD/MAS-associated <i>GNAS</i> variants at residues p.Arg201 and p.Gln227 disrupt the activity of intrinsic GTPase, causing constitutive activity and inappropriately increased cAMP signaling [<a class="bk_pop" href="#mccune-albright.REF.landis.1989.692">Landis et al 1989</a>].</p><p>The spectrum of FD/MAS ranges from asymptomatic incidental findings to neonatal lethality. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of FD/MAS is a reflection of the role of G<sub>s</sub>&#x003b1; in that tissue and whether or not a given tissue harbors a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>GNAS</i>. The distribution of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues is a reflection of the timing of the occurrence of the <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> pathogenic variant during development and the fate of the specific clone in which the pathogenic variant occurs. It is likely that the stem cells of certain tissues will not tolerate mutated G<sub>s</sub>&#x003b1; and are eliminated during development. Therefore, some tissues in which there is significant G<sub>s</sub>&#x003b1; signaling will not be affected. For example, G<sub>s</sub>&#x003b1; signaling is important in growth plate development, yet the growth plate is virtually never affected.</p><p>Activating or <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> <i>GNAS</i> pathogenic variants in individuals with FD/MAS are present in the mosaic state, resulting from postzygotic somatic pathogenic variants appearing early in the course of development, which yields a monoclonal population of mutated cells within variously <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues. The non-mosaic state for most activating pathogenic variants is presumably lethal to the embryo (modified from OMIM <a href="http://omim.org/entry/174800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">174800</a>).</p><div id="mccune-albright.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p>The FD/MAS-associated activating <i>GNAS</i> pathogenic variants at residues p.Arg201 and p.Gln227 (collectively referred to as the <i>gsp</i> oncogene) have been reported in nonsyndromic benign [<a class="bk_pop" href="#mccune-albright.REF.landis.1989.692">Landis et al 1989</a>] and malignant [<a class="bk_pop" href="#mccune-albright.REF.wood.2007.1108">Wood et al 2007</a>] tumors. However, the presence of the <i>GNAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> alone is insufficient for malignant transformation of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> tissues, but more likely predisposes for additional genetic or epigenetic events.</p></div></div><div id="mccune-albright.References"><h2 id="_mccune-albright_References_">References</h2><div id="mccune-albright.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.amit.2011.e25179">Amit M, Collins MT, FitzGibbon EJ, Butman JA, Fliss DM, Gil Z. Surgery versus watchful waiting in patients with craniofacial fibrous dysplasia--a meta-analysis. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e25179.</span> [<a href="/pmc/articles/PMC3179490/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3179490</span></a>] [<a href="/pubmed/21966448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21966448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.benhamou.2014.549">Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. <span><span class="ref-journal">Joint Bone Spine. </span>2014;<span class="ref-vol">81</span>:549–50.</span> [<a href="/pubmed/24962974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24962974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.bhattacharyya.2012.1132">Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT. Mechanism of FGF23 processing in fibrous dysplasia. <span><span class="ref-journal">J Bone Miner Res. </span>2012;<span class="ref-vol">27</span>:1132–41.</span> [<a href="/pubmed/22247037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22247037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.bianco.2000.120">Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey PG. Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. <span><span class="ref-journal">J Bone Miner Res. </span>2000;<span class="ref-vol">15</span>:120–8.</span> [<a href="/pubmed/10646121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10646121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.boyce.2018.102">Boyce AM, Brewer C, DeKlotz TR, Zalewski CK, King KA, Collins MT, Kim HJ. Association of hearing loss and otologic outcomes with fibrous dysplasia. <span><span class="ref-journal">JAMA Otolaryngol Head Neck Surg. </span>2018;<span class="ref-vol">144</span>:102–7.</span> [<a href="/pmc/articles/PMC5839293/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5839293</span></a>] [<a href="/pubmed/29192304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29192304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.boyce.2012a.e1782">Boyce AM, Chong WH, Shawker TH, Pinto PA, Linehan WM, Bhattacharryya N, Merino MJ, Singer FR, Collins MT. Characterization and management of testicular pathology in McCune-Albright syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2012a;<span class="ref-vol">97</span>:E1782–90.</span> [<a href="/pmc/articles/PMC3431566/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3431566</span></a>] [<a href="/pubmed/22745241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22745241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.boyce.2012b.1462">Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT. Denosumab treatment for fibrous dysplasia. <span><span class="ref-journal">J Bone Miner Res. </span>2012b;<span class="ref-vol">27</span>:1462–70.</span> [<a href="/pmc/articles/PMC3377825/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3377825</span></a>] [<a href="/pubmed/22431375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22431375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.boyce.2013.e126">Boyce AM, Glover M, Kelly MH, Brillante BA, Butman JA, Fitzgibbon EJ, Brewer CC, Zalewski CK, Cutler Peck CM, Kim HJ, Collins MT. Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:E126–34.</span> [<a href="/pmc/articles/PMC3537097/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3537097</span></a>] [<a href="/pubmed/23093488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23093488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.boyce.2014.4133">Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M, Bianco P, Robey PG, Collins MT. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2014;<span class="ref-vol">99</span>:4133–40.</span> [<a href="/pmc/articles/PMC4223439/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4223439</span></a>] [<a href="/pubmed/25033066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25033066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.brown.2010.1508">Brown RJ, Kelly MH, Collins MT. Cushing syndrome in the McCune-Albright syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010;<span class="ref-vol">95</span>:1508–15.</span> [<a href="/pmc/articles/PMC2853983/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2853983</span></a>] [<a href="/pubmed/20157193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20157193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.carney.2011.1311">Carney JA, Young WF, Stratakis CA. Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune-Albright syndrome. <span><span class="ref-journal">Am J Surg Pathol. </span>2011;<span class="ref-vol">35</span>:1311–26.</span> [<a href="/pmc/articles/PMC4140081/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4140081</span></a>] [<a href="/pubmed/21836496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21836496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.celi.2008.2383">Celi FS, Coppotelli G, Chidakel A, Kelly M, Brillante BA, Shawker T, Cherman N, Feuillan PP, Collins MT. The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2008;<span class="ref-vol">93</span>:2383–9.</span> [<a href="/pmc/articles/PMC2435649/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2435649</span></a>] [<a href="/pubmed/18349068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18349068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.clark.2000.204">Clark TJ, Tan BK, Kennedy CR. Asynchronous ovarian torsion in a patient with McCune-Albright syndrome. <span><span class="ref-journal">J Obstet Gynaecol. </span>2000;<span class="ref-vol">20</span>:204.</span> [<a href="/pubmed/15512529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15512529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.collins.2001.806">Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. <span><span class="ref-journal">J Bone Miner Res. </span>2001;<span class="ref-vol">16</span>:806–13.</span> [<a href="/pubmed/11341325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11341325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.collins.2005.219">Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. <span><span class="ref-journal">J Bone Miner Res. </span>2005;<span class="ref-vol">20</span>:219–26.</span> [<a href="/pubmed/15647815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15647815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.collins.2003.4413">Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2003;<span class="ref-vol">88</span>:4413–7.</span> [<a href="/pubmed/12970318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12970318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.cox.2017.589">Cox JL, Cushman-Vokoun AM, McGarry SV, Kozel JA. Two cases of Mazabraud syndrome and identification of a GNAS R201H mutation by next-generation sequencing. <span><span class="ref-journal">Virchows Arch. </span>2017;<span class="ref-vol">470</span>:589–93.</span> [<a href="/pubmed/28258512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28258512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.cutler.2006.1011">Cutler CM, Lee JS, Butman JA, FitzGibbon EJ, Kelly MH, Brillante BA, Feuillan P, Robey PG, DuFresne CR, Collins MT. Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. <span><span class="ref-journal">Neurosurgery. </span>2006;<span class="ref-vol">59</span>:1011–7.</span> [<a href="/pubmed/17143235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17143235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.de_sanctis.2017.342">de Sanctis L, Galliano I, Montanari P, Matarazzo P, Tessaris D, Bergallo M. Combining real-time COLD- and MAMA-PCR TaqMan techniques to detect and quantify R201 GNAS mutations in the McCune-Albright syndrome. <span><span class="ref-journal">Horm Res Paediatr. </span>2017;<span class="ref-vol">87</span>:342–9.</span> [<a href="/pubmed/28334704" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28334704</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.estrada.2016.477">Estrada A, Boyce AM, Brillante BA, Guthrie LC, Gafni RI, Collins MT. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome. <span><span class="ref-journal">Eur J Endocrinol. </span>2016;<span class="ref-vol">175</span>:477–83.</span> [<a href="/pmc/articles/PMC5066167/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5066167</span></a>] [<a href="/pubmed/27562402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27562402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.feuillan.2007.2100">Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007;<span class="ref-vol">92</span>:2100–6.</span> [<a href="/pubmed/17405850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17405850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.ganda.2014.777">Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. <span><span class="ref-journal">Osteoporos Int. </span>2014;<span class="ref-vol">25</span>:777–82.</span> [<a href="/pubmed/24311113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24311113</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.gaujoux.2014.e97">Gaujoux S, Salenave S, Ronot M, Rangheard AS, Cros J, Belghiti J, Sauvanet A, Ruszniewski P, Chanson P. Hepatobiliary and pancreatic neoplasms in patients with McCune-Albright syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2014;<span class="ref-vol">99</span>:E97–101.</span> [<a href="/pubmed/24170100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24170100</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.hansen.2003.79">Hansen MR, Moffat JC. Osteosarcoma of the skull base after radiation therapy in a patient with McCune-Albright syndrome: case report. <span><span class="ref-journal">Skull Base. </span>2003;<span class="ref-vol">13</span>:79–83.</span> [<a href="/pmc/articles/PMC1131834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1131834</span></a>] [<a href="/pubmed/15912163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15912163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.hart.2007.1468">Hart ES, Kelly MH, Brillante B, Chen CC, Ziran N, Lee JS, Feuillan P, Leet AI, Kushner H, Robey PG, Collins MT. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. <span><span class="ref-journal">J Bone Miner Res. </span>2007;<span class="ref-vol">22</span>:1468–74.</span> [<a href="/pubmed/17501668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17501668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.idowu.2007.691">Idowu BD, Al-Adnani M, O'Donnell P, Yu L, Odell E, Diss T, Gale RE, Flanagan AM. A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. <span><span class="ref-journal">Histopathology. </span>2007;<span class="ref-vol">50</span>:691–704.</span> [<a href="/pubmed/17493233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17493233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.ikawa.2016.298">Ikawa Y, Yachi Y, Inoue N, Kato A, Okajima M, Yachie A. Neonatal McCune-Albright syndrome with giant cell hepatitis. <span><span class="ref-journal">J Pediatr. </span>2016;<span class="ref-vol">178</span>:298.</span> [<a href="/pubmed/27592093" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27592093</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.kalfa.2006.839">Kalfa N, Philibert P, Audran F, Ecochard A, Hannon T, Lumbroso S, Sultan C. Searching for somatic mutations in McCune-Albright syndrome: a comparative study of the peptidic nucleic acid versus the nested PCR method based on 148 DNA samples. <span><span class="ref-journal">Eur J Endocrinol. </span>2006;<span class="ref-vol">155</span>:839–43.</span> [<a href="/pubmed/17132753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17132753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.katznelson.2014.3933">Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA. Acromegaly: an endocrine society clinical practice guideline. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2014;<span class="ref-vol">99</span>:3933–51.</span> [<a href="/pubmed/25356808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25356808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.kelly.2008.57">Kelly MH, Brillante B, Collins MT. Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. <span><span class="ref-journal">Osteoporos Int. </span>2008;<span class="ref-vol">19</span>:57–63.</span> [<a href="/pubmed/17622477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17622477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.kelly.2005.388">Kelly MH, Brillante B, Kushner H, Gehron Robey P, Collins MT. Physical function is impaired but quality of life preserved in patients with fibrous dysplasia of bone. <span><span class="ref-journal">Bone. </span>2005;<span class="ref-vol">37</span>:388–94.</span> [<a href="/pubmed/15963775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15963775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.kuznetsov.2008.1731">Kuznetsov SA, Cherman N, Riminucci M, Collins MT, Robey PG, Bianco P. Age-dependent demise of GNAS-mutated skeletal stem cells and "normalization" of fibrous dysplasia of bone. <span><span class="ref-journal">J Bone Miner Res. </span>2008;<span class="ref-vol">23</span>:1731–40.</span> [<a href="/pmc/articles/PMC2585500/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2585500</span></a>] [<a href="/pubmed/18597624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18597624</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.lala.2007.423">Lala R, Andreo M, Pucci A, Matarazzo P. Persistent hyperestrogenism after precocious puberty in young females with McCune-Albright syndrome. <span><span class="ref-journal">Pediatr Endocrinol Rev. </span>2007;<span class="ref-vol">4</span> Suppl 4:423–8.</span> [<a href="/pubmed/17982390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17982390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.landis.1989.692">Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. <span><span class="ref-journal">Nature. </span>1989;<span class="ref-vol">340</span>:692–6.</span> [<a href="/pubmed/2549426" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2549426</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.lawless.1992.1099">Lawless ST, Reeves G, Bowen JR. The development of thyroid storm in a child with McCune-Albright syndrome after orthopedic surgery. <span><span class="ref-journal">Am J Dis Child. </span>1992;<span class="ref-vol">146</span>:1099–102.</span> [<a href="/pubmed/1514560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1514560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.lee.2012.s2">Lee JS, FitzGibbon EJ, Chen YR, Kim HJ, Lustig LR, Akintoye SO, Collins MT, Kaban LB. Clinical guidelines for the management of craniofacial fibrous dysplasia. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span> Suppl 1:S2.</span> [<a href="/pmc/articles/PMC3359960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3359960</span></a>] [<a href="/pubmed/22640797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22640797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.lee.2002.1670">Lee JS, FitzGibbon E, Butman JA, Dufresne CR, Kushner H, Wientroub S, Robey PG, Collins MT. Normal vision despite narrowing of the optic canal in fibrous dysplasia. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">347</span>:1670–6.</span> [<a href="/pubmed/12444181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12444181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.leet.2016.211">Leet AI, Boyce AM, Ibrahim KA, Wientroub S, Kushner H, Collins MT. Bone-grafting in polyostotic fibrous dysplasia. <span><span class="ref-journal">J Bone Joint Surg Am. </span>2016;<span class="ref-vol">98</span>:211–9.</span> [<a href="/pmc/articles/PMC4732545/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4732545</span></a>] [<a href="/pubmed/26842411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26842411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.leet.2004a.571">Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. <span><span class="ref-journal">J Bone Miner Res. </span>2004a;<span class="ref-vol">19</span>:571–7.</span> [<a href="/pubmed/15005844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15005844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.leet.2004b.531">Leet AI, Magur E, Lee JS, Wientroub S, Robey PG, Collins MT. Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis. <span><span class="ref-journal">J Bone Joint Surg Am. </span>2004b;<span class="ref-vol">86</span>:531–7.</span> [<a href="/pubmed/14996879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14996879</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.lim.2014.397">Lim YH, Ovejero D, Sugarman JS, Deklotz CM, Maruri A, Eichenfield LF, Kelley PK, J&#x000fc;ppner H, Gottschalk M, Tifft CJ, Gafni RI, Boyce AM, Cowen EW, Bhattacharyya N, Guthrie LC, Gahl WA, Golas G, Loring EC, Overton JD, Mane SM, Lifton RP, Levy ML, Collins MT, Choate KA. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:397–407.</span> [<a href="/pmc/articles/PMC3869357/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3869357</span></a>] [<a href="/pubmed/24006476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24006476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.liu.2011.283">Liu F, Li W, Yao Y, Li G, Yang Y, Dou W, Zhong D, Wang L, Zhu X, Hu H, Zhang J, Wang R, Chen G. A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy. <span><span class="ref-journal">J Pediatr Endocrinol Metab. </span>2011;<span class="ref-vol">24</span>:283–7.</span> [<a href="/pubmed/21823524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21823524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.lumbroso.2004.2107">Lumbroso S, Paris F, Sultan C., European Collaborative Study.  Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:2107–13.</span> [<a href="/pubmed/15126527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15126527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.mahdi.2017.179">Mahdi AJ, Connor P, Thakur I. McCune-Albright syndrome-associated bone marrow failure and extramedullary haematopoeisis secondary to fibrous dysplasia. <span><span class="ref-journal">Br J Haematol. </span>2017;<span class="ref-vol">178</span>:179.</span> [<a href="/pubmed/28612379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28612379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.majoor.2018a.84">Majoor BC, Boyce AM, Bov&#x000e9;e JV, Smit VT, Collins MT, Cleton-Jansen AM, Dekkers OM, Hamdy NA, Dijkstra PS, Appelman-Dijkstra NM. Increased risk of breast cancer at a young age in women with fibrous dysplasia. <span><span class="ref-journal">J Bone Miner Res. </span>2018a;<span class="ref-vol">33</span>:84–90.</span> [<a href="/pubmed/28856726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28856726</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.majoor.2018b.23">Majoor BCJ, Andela CD, Quispel CR. Rotman M2, Dijkstra PDS, Hamdy NAT, Kaptein AA, Appelman-Dijkstra NM. Illness perceptions are associated with quality of life in patients with fibrous dysplasia. <span><span class="ref-journal">Calcif Tissue Int. </span>2018b;<span class="ref-vol">102</span>:23–31.</span> [<a href="/pmc/articles/PMC5760610/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5760610</span></a>] [<a href="/pubmed/29022055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29022055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.mancini.2009.196">Mancini F, Corsi A, De Maio F, Riminucci M, Ippolito E. Scoliosis and spine involvement in fibrous dysplasia of bone. <span><span class="ref-journal">Eur Spine J. </span>2009;<span class="ref-vol">18</span>:196–202.</span> [<a href="/pmc/articles/PMC2899336/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2899336</span></a>] [<a href="/pubmed/19130098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19130098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.manjila.2013.1183">Manjila S, Zender CA, Weaver J, Rodgers M, Cohen AR. Aneurysmal bone cyst within fibrous dysplasia of the anterior skull base: continued intracranial extension after endoscopic resections requiring craniofacial approach with free tissue transfer reconstruction. <span><span class="ref-journal">Childs Nerv Syst. </span>2013;<span class="ref-vol">29</span>:1183–92.</span> [<a href="/pubmed/23435492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23435492</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.mariot.2011">Mariot V, Wu JY, Aydin C, Mantovani G, Mahon MJ, Linglart A, Bastepe M. Potent constitutive cyclic AMP-generating activity of XL&#x003b1;s implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. <a href="https://www.ncbi.nlm.nih.gov/pubmed/20887824" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bone<wbr style="display:inline-block"></wbr>​.</a> 2011;48:312-20. [<a href="/pmc/articles/PMC3021591/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3021591</span></a>] [<a href="/pubmed/20887824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20887824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.narumi.2013.e60525">Narumi S, Matsuo K, Ishii T, Tanahashi Y, Hasegawa T. Quantitative and sensitive detection of GNAS mutations causing McCune-Albright syndrome with next generation sequencing. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e60525.</span> [<a href="/pmc/articles/PMC3607597/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3607597</span></a>] [<a href="/pubmed/23536913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23536913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.ovejero.2016.3615">Ovejero D, Lim YH, Boyce AM, Gafni RI, McCarthy E, Nguyen TA, Eichenfield LF, DeKlotz CM, Guthrie LC, Tosi LL, Thornton PS, Choate KA, Collins MT. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. <span><span class="ref-journal">Osteoporos Int. </span>2016;<span class="ref-vol">27</span>:3615–26.</span> [<a href="/pmc/articles/PMC6908308/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6908308</span></a>] [<a href="/pubmed/27497815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27497815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.parvanescu.2014.858">Parvanescu A, Cros J, Ronot M, Hentic O, Grybek V, Couvelard A, Levy P, Chanson P, Ruszniewski P, Sauvanet A, Gaujoux S. Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess. <span><span class="ref-journal">JAMA Surg. </span>2014;<span class="ref-vol">149</span>:858–62.</span> [<a href="/pubmed/24898823" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24898823</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.paul.2014.41">Paul SM, Gabor LR, Rudzinski S, Giovanni D, Boyce AM, Kelly MR, Collins MT. Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia. <span><span class="ref-journal">Bone. </span>2014;<span class="ref-vol">60</span>:41–7.</span> [<a href="/pmc/articles/PMC3985279/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3985279</span></a>] [<a href="/pubmed/24316419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24316419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.riminucci.2003.683">Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. <span><span class="ref-journal">J Clin Invest. </span>2003;<span class="ref-vol">112</span>:683–92.</span> [<a href="/pmc/articles/PMC182207/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC182207</span></a>] [<a href="/pubmed/12952917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12952917</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.robinson.2018.237">Robinson C, Boyce AM, Estrada A, Kleiner DE, Mathew R, Stanton R, Frangoul H, Collins MT. Bone marrow failure and extramedullary hematopoiesis in McCune-Albright syndrome. <span><span class="ref-journal">Osteoporos Int. </span>2018;<span class="ref-vol">29</span>:237–41.</span> [<a href="/pubmed/29071359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29071359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.ross.2016.1343">Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <span><span class="ref-journal">Thyroid. </span>2016;<span class="ref-vol">26</span>:1343–1421.</span> [<a href="/pubmed/27521067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27521067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.ruggieri.1994.1411">Ruggieri P, Sim FH, Bond JR, Unni KK. Malignancies in fibrous dysplasia. <span><span class="ref-journal">Cancer. </span>1994;<span class="ref-vol">73</span>:1411–24.</span> [<a href="/pubmed/8111708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8111708</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.salenave.2014.1955">Salenave S, Boyce AM, Collins MT, Chanson P. Acromegaly and McCune-Albright syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2014;<span class="ref-vol">99</span>:1955–69.</span> [<a href="/pmc/articles/PMC4037730/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4037730</span></a>] [<a href="/pubmed/24517150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24517150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.silva.2000.154">Silva ES, Lumbroso S, Medina M, Gillerot Y, Sultan C, Sokal EM. Demonstration of McCune-Albright mutations in the liver of children with high gammaGT progressive cholestasis. <span><span class="ref-journal">J Hepatol. </span>2000;<span class="ref-vol">32</span>:154–8.</span> [<a href="/pubmed/10673080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10673080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.stanton.2012.s1">Stanton RP, Ippolito E, Springfield D, Lindaman L, Wientroub S, Leet A. The surgical management of fibrous dysplasia of bone. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span> Suppl 1:S1.</span> [<a href="/pmc/articles/PMC3359959/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3359959</span></a>] [<a href="/pubmed/22640754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22640754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.tanaka.2012.183">Tanaka M, Fern&#x000e1;ndez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K., et al.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. <span><span class="ref-journal">Pancreatology. </span>2012;<span class="ref-vol">12</span>:183–97.</span> [<a href="/pubmed/22687371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22687371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.tessaris.2012.151">Tessaris D, Corrias A, Matarazzo P, De Sanctis L, Wasniewska M, Messina MF, Vigone MC, Lala R. Thyroid abnormalities in children and adolescents with McCune-Albright syndrome. <span><span class="ref-journal">Horm Res Paediatr. </span>2012;<span class="ref-vol">78</span>:151–7.</span> [<a href="/pubmed/23006743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23006743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.vortmeyer.2012.2404">Vortmeyer AO, Gl&#x000e4;sker S, Mehta GU, Abu-Asab MS, Smith JH, Zhuang Z, Collins MT, Oldfield EH. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2012;<span class="ref-vol">97</span>:2404–13.</span> [<a href="/pmc/articles/PMC3791436/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3791436</span></a>] [<a href="/pubmed/22564667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22564667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.weinstein.2004.5459">Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. Minireview: GNAS: normal and abnormal functions. <span><span class="ref-journal">Endocrinology. </span>2004;<span class="ref-vol">145</span>:5459–64.</span> [<a href="/pubmed/15331575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15331575</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.wood.2017.391">Wood LD, No&#x000eb; M, Hackeng W, Brosens LA, Bhaijee F, Debeljak M, Yu J, Suenaga M, Singhi AD, Zaheer A, Boyce A, Robinson C, Eshleman JR, Goggins MG, Hruban RH, Collins MT, Lennon AM, Montgomery EA. Patientes with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. <span><span class="ref-journal">Virchows Arch. </span>2017;<span class="ref-vol">470</span>:391–400.</span> [<a href="/pmc/articles/PMC5376511/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5376511</span></a>] [<a href="/pubmed/28188442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28188442</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mccune-albright.REF.wood.2007.1108">Wood LD, Parsons DW, Jones S, Lin J, Sj&#x000f6;blom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. <span><span class="ref-journal">Science. </span>2007;<span class="ref-vol">318</span>:1108–13.</span> [<a href="/pubmed/17932254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17932254</span></a>]</div></li></ul></div></div><div id="mccune-albright.Chapter_Notes"><h2 id="_mccune-albright_Chapter_Notes_">Chapter Notes</h2><div id="mccune-albright.Author_Notes"><h3>Author Notes</h3><p>Alison M Boyce, MD is a pediatric endocrinologist who specializes in the evaluation and treatment of bone disorders in children and adolescents. She performs clinical research in FD/MAS and other pediatric skeletal diseases at the National Institutes of Health.</p><p>Pablo Florenzano, MD is an endocrinologist who specializes in the evaluation and treatment of bone disorders in adults. He performs clinical research at Pontificia Universidad Catolica de Chile, primarily in disorders of bone and mineral homeostasis.</p><p>Luis Fernandez de Castro Diaz, PhD is a staff scientist in the Skeletal Disorders and Mineral Homeostasis Section. He performs basic and translational research primarily in disorders of bone and mineral homeostasis.</p><p>Michael T Collins, MD is an endocrinologist who conducts translation research at the National Institutes of Health. He studies and treats primarily patients with rare disorders of bone and mineral homeostasis, including FD/MAS.</p></div><div id="mccune-albright.Acknowledgments"><h3>Acknowledgments</h3><p>This research was supported by the Intramural Research Program of the NIH, NIDCR (AMB, MTC) and the Bone Health Program, Division of Orthopaedics and Sports Medicine, Children's National Health System (AMB). The authors are grateful to the patients and their families for participation in the research and the efforts of the trainees of the NIH Interinstitute Endocrine Training Program for the excellent care they provide to our research subjects at the NIH Mark O Hatfield Clinical Research Center.</p></div><div id="mccune-albright.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>27 June 2019 (ma) Revision: Management section</div></li><li class="half_rhythm"><div>16 August 2018 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 February 2015 (me) Review posted live</div></li><li class="half_rhythm"><div>17 October 2014 (amb) Original submission</div></li></ul></div></div><div style="display:none"><div style="display:none" id="figmccunealbrightF5"><img alt="Image mccune-albright-Image001" src-large="/books/NBK274564/bin/mccune-albright-Image001.jpg" /></div><div style="display:none" id="figmccunealbrightF6"><img alt="Image mccune-albright-Image002" src-large="/books/NBK274564/bin/mccune-albright-Image002.jpg" /></div><div style="display:none" id="figmccunealbrightF7"><img alt="Image mccune-albright-Image003" src-large="/books/NBK274564/bin/mccune-albright-Image003.jpg" /></div><div style="display:none" id="figmccunealbrightF8"><img alt="Image mccune-albright-Image004" src-large="/books/NBK274564/bin/mccune-albright-Image004.jpg" /></div><div style="display:none" id="figmccunealbrightF9"><img alt="Image mccune-albright-Image005" src-large="/books/NBK274564/bin/mccune-albright-Image005.jpg" /></div><div style="display:none" id="figmccunealbrightF10"><img alt="Image mccune-albright-Image006" src-large="/books/NBK274564/bin/mccune-albright-Image006.jpg" /></div><div style="display:none" id="figmccunealbrightF11"><img alt="Image mccune-albright-Image007" src-large="/books/NBK274564/bin/mccune-albright-Image007.jpg" /></div><div style="display:none" id="figmccunealbrightF12"><img alt="Image mccune-albright-Image008" src-large="/books/NBK274564/bin/mccune-albright-Image008.jpg" /></div><div style="display:none" id="figmccunealbrightF13"><img alt="Image mccune-albright-Image009" src-large="/books/NBK274564/bin/mccune-albright-Image009.jpg" /></div><div style="display:none" id="figmccunealbrightF14"><img alt="Image mccune-albright-Image010" src-large="/books/NBK274564/bin/mccune-albright-Image010.jpg" /></div><div style="display:none" id="figmccunealbrightF15"><img alt="Image mccune-albright-Image011" src-large="/books/NBK274564/bin/mccune-albright-Image011.jpg" /></div><div style="display:none" id="figmccunealbrightF16"><img alt="Image mccune-albright-Image012" src-large="/books/NBK274564/bin/mccune-albright-Image012.jpg" /></div><div style="display:none" id="figmccunealbrightF17"><img alt="Image mccune-albright-Image013" src-large="/books/NBK274564/bin/mccune-albright-Image013.jpg" /></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK274564</span><span class="label">PMID: <a href="/pubmed/25719192" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">25719192</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/feingold/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fhs/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK274564&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK274564/?report=reader">PubReader</a></li><li><a href="/books/NBK274564/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK274564" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK274564" style="display:none" title="Cite this Page"><div class="bk_tt">Boyce AM, Florenzano P, de Castro LF, et al. Fibrous Dysplasia/McCune-Albright Syndrome. 2015 Feb 26 [Updated 2019 Jun 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK274564/pdf/Bookshelf_NBK274564.pdf">PDF version of this page</a> (1.7M)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mccune-albright.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mccune-albright.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mccune-albright.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#mccune-albright.Genetically_Related_Alle" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mccune-albright.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mccune-albright.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mccune-albright.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mccune-albright.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mccune-albright.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mccune-albright.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mccune-albright.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2778[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GNAS</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3396392" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3396392" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3396392" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3396392" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29599748" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.</a><span class="source">[Front Endocrinol (Lausanne). 2...]</span><div class="brieflinkpop offscreen_noflow">Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Utriainen P, Valta H, Björnsdottir S, Mäkitie O, Horemuzova E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Front Endocrinol (Lausanne). 2018; 9:96. Epub 2018 Mar 15.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18489744" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">McCune-Albright syndrome.</a><span class="source">[Orphanet J Rare Dis. 2008]</span><div class="brieflinkpop offscreen_noflow">McCune-Albright syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dumitrescu CE, Collins MT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2008 May 19; 3:12. Epub 2008 May 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28520344" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> McCune-Albright Syndrome</a><span class="source">[Medical Genetics Summaries. 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> McCune-Albright Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dean L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Medical Genetics Summaries. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16789617" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> McCune-Albright syndrome: clinical picture and natural history in children and adolescents.</a><span class="source">[J Pediatr Endocrinol Metab. 2006]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> McCune-Albright syndrome: clinical picture and natural history in children and adolescents.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Völkl TM, Dörr HG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Pediatr Endocrinol Metab. 2006 May; 19 Suppl 2:551-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22640971" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.</a><span class="source">[Orphanet J Rare Dis. 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Collins MT, Singer FR, Eugster E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2012 May 24; 7 Suppl 1:S4. Epub 2012 May 24.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=25719192" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=25719192" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041ad275f66d18aab85a7b">Fibrous Dysplasia/McCune-Albright Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Fibrous Dysplasia/McCune-Albright Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:28:34-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89A9A4E04137810000000003C601A8&amp;ncbi_session=CE89A9A4E041AD01_0966SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK274564%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK274564&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK274564/&amp;ncbi_pagename=Fibrous Dysplasia/McCune-Albright Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89A9A4E041AD01_0966SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>